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Abstract
Loss of ATRX Confers DNA Repair Defects and PARP Inhibitor Sensitivity in Glioma
Jennifer Mary Garbarino
2021
Alpha Thalassemia/Mental Retardation Syndrome X-Linked (ATRX) is mutated frequently in
gliomas and represents a potential target for cancer therapeutics development. ATRX is known
to function as a histone chaperone that incorporates the histone variant, H3.3, into the genome.
Studies have implicated ATRX in key DNA damage response (DDR) pathways, including nonhomologous end joining (NHEJ), homologous recombination (HR), and replication stress
response, but a distinct role for this protein in DNA repair has yet to be fully elucidated. To
further investigate ATRX function in glioma, I created CRISPR knockout clones in multiple
glioma cell lines. These cell lines were found to have DNA repair defects that indicated
increased replication stress. I then determined that the immortalized astrocyte ATRX KO cell
line is sensitive to PARP inhibitors. This sensitivity is due to an increase in replication stress
identified through increased ATR activation. The DNA repair defect in these cells overlaps with
a frequently co-occurring mutation in gliomas, IDH1 R132H, and so leads to equal sensitivity
compared to either mutation alone. I also performed a CRISPR screen which highlighted the
importance of the chromatin modifications made by ATRX and how knockout cells are more
susceptible to chromatin instability. Taken together, these data reveal that ATRX may be used as
a molecular marker for DDR defects and PARP inhibitor sensitivity, which is independent of
IDH1/2 mutations. These data highlight the important role of common glioma-associated
mutations in the regulation of DDR, and they highlight novel avenues for molecularly guided
therapeutic intervention.
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1. Introduction
Alpha Thalassemia Retardation syndrome X-linked (ATRX) is chromatin modifier that is
mutated frequently in gliomas. Its main function is to incorporate histone 3.3 into specific
regions of the genome, such as telomeres, heterochromatin, rRNA and pericentric
heterochromatin regions (Figure 1.1) (Dyer et al., 2017). It has been widely studied for its role
in chromatin maintenance and DNA repair, but more work needs to be done to further
characterize this protein.

Figure 1.1: Regions of ATRX chromosomal localization
ATRX localizes at distinct regions of the genome such as telomers, facultative
heterochromatin, pericentric heterochromatin and repetitive regions. While DAXX is
important for the incorporation of H3.3 in these regions, there are other factors specific
to each of these areas that can interact with ATRX. Image from (Dyer et al., 2017)
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1.1. Discovery
ATRX was first identified through mutational analysis of patients with ATRX syndrome, a
developmental disorder that leads to various symptoms such as alpha globin deficiencies (alpha
thalassemia), facial deformities, psychomotor retardation and other abnormalities (Gibbons et al.,
1995; Higgs et al., 2000). As ATRX is found on the X-chromosome, these symptoms are
primarily seen in men, with heterozygous women having only mild affects (Gibbons et al.,
1995).
ATRX mutation was found to cause alpha globin deficiencies (alpha thalassemia) through
decrease in mRNA expression. This gene is very close to a telomere and GC-rich, both locations
where ATRX normally is targeted (Law et al., 2010). Further work has also found that ATRX’s
role in alpha globin expression could be due to its lesser known role as a regulator of histone
macroH2A.1 (Ratnakumar et al., 2012). Since its discovery, ATRX has been studied for its
function not only in this genetic disorder, but also when it is mutated in glioma.
1.2. Mutations in Glioma
ATRX is mutated frequently in glioma, the most common form of brain cancer (He et al.,
2018). Up to forty percent of low grade gliomas have ATRX mutation, as well as 7% of
glioblastoma multiforme, 9% of diffuse pontine gliomas, and 15% of high risk neuroblastoma
(Haase et al., 2018). These mutations tend to occur throughout the length of the protein, and
mostly lead to truncation of the protein (Cerami et al., 2012). This leads to a lack of expression,
which can be tested for in the clinic (Reifenberger et al., 2016).
Due to this frequent mutation, ATRX status is used diagnostically in the clinic to characterize
these tumors (Reifenberger et al., 2016). As seen in Figure 1.3, ATRX expression status is used
2

as one of four clinical markers utilized to identify specific differences between astrocytoma and
oligodendroglioma.
Also seen in Figure 1.3, ATRX in these classifications is always associated with IDH1
mutation. These mutations co-occur very frequently and so their characterization together is very
important. In fact, ATRX mutation often co-occurs with many other common glioma and
glioblastoma mutations. ATRX mutation occurs in three different glioblastoma molecular
subgroups (Figure 1.2). However, IDH1 R132H mutation is the most common, as IDH1
mutation cooccurs in up to 90% of ATRX mutant cases (Cerami et al., 2012).
ATRX is an important diagnostic marker in glioma and glioblastoma. These mutations are
mostly truncating and so while there are few common mutations between tumors, the lack of
ATRX expression is common to these cancers (Cerami et al., 2012). Utilizing initial work done
on ATRX to further understand ATRX syndrome, many studies have been done to identify
potential mechanism of action of ATRX loss in cancer.

3

Figure 1.3 ATRX expression status is used diagnostically in the clinic
ATRX expression is an important marker clinically for determining a specific diagnosis
for glioma and glioblastoma. Image from (Reifenberger et al., 2016)

Figure 1.2: ATRX mutation co-occurs with other common glioma mutations.
ATRX mutation is found in multiple molecular subgroups of glioblastoma (underlined in
red). Specifically, ATRX mutation can occur with IDH1 mutation, histone 3 mutations
and MGMT promoter methylation. Image from (Reifenberger et al., 2016)
4

1.3. Role in chromatin modification
ATRX is a 300 kda protein with 2 domains: the n-terminal ATRX-DNMT3-DNMT2L
(ADD) domain and the C-terminal ATP SNF2 type remodeling domain (Iwase et al., 2011). It is
known to incorporate histone 3.3 into repetitive, often silenced parts of the genome. Histone 3.3
differs from H3.1 and H3.2 by only 5 amino acids. This allows H3.3 to have an additional
phosphorylation site at S31. H3.3 is incorporated throughout the cell cycle into transcriptional
areas by HIRA and to more repetitive regions, such as telomeres and heterochromatin by ATRX
and DAXX (Szenker et al., 2011). DAXX and ATRX work together to incorporate H3.3 in these
regions and often exist bound together (Lewis et al., 2010). DAXX binds the histone 3.3 being
incorporated, and then ATRX recruits this complex to regions such as the telomere for histone
incorporation. ATRX has been found to localize to these regions both during and independent
from replication (Lewis et al., 2010; Wong et al., 2010).
ATRX’s role in histone incorporation can lead to overall epigenetic changes in cells deficient
in ATRX. Loss of ATRX can lead to an increase in H3.3 throughout the genome as it is not
being specifically incorporated into telomeres and other repeat regions (Danussi et al., 2018).
Histone 3.3 is incorporated into other euchromatin regions of the genome by the protein HIRA,
which would now have a greater supply of the histone (Voon et al., 2015). There is also evidence
of an increase in DNA methylation in regions such as telomeres with ATRX deficiency (Cai et
al., 2015). These epigenetic changes lead to large differences in gene expression with ATRX KO
that can lead to increased migration and changes in differentiation, which could help drive
ATRX mutant cancers (Cai et al., 2015; Danussi et al., 2018; Oppel et al., 2019).
ATRX is targeted to the telomeres and heterochromatin by binding to H3K9 trimethylation
(Iwase et al., 2011). This methylation, performed by SETDB1 and SUV39h1/2, is known for its
5

role as a mark in heterochromatin, an important modification of H3.3 at telomeres. ATRX
localization to this methylation occurs through its ADD domain. The ADD domain binds this
trimethylation and so can be used to help properly locate ATRX to heterochromatin. Additional
binding factors such as Mcep2 and Hp1α have been seen in mouse cells to play an important role
in ATRX localization as well. Both of these proteins bind to ATRX and have some evidence of
being necessary for ATRX recruitment (Iwase et al., 2011; Udugama et al., 2018).
It has been shown that loss of H3.3 causes a loss of chromatin repression and ATRX levels
at telomeres and rDNA (Udugama et al., 2015, 2018). Interestingly, loss of H3.3 and ATRX
have similar effects, indicating the importance of ATRX’s incorporation of H3.3 at these regions
(Udugama et al., 2015). This marker is also seen at other repeat regions such as ribosomal DNA
(Udugama et al., 2018) and pericentric heterochromatin (Iwase et al., 2011; Voon et al., 2015;
Wong et al., 2010).
In addition to its role in incorporation of H3.3, ATRX is also a regulator of macroH2A1. A
variant of H2A, macroH2A1 is nearly three times larger than typical histones with a large nonhistone C-terminal region causing the size increase to 42 kda (Pehrson and Fried, 1992). This
histone variant has two isoforms, macroH2A1.1 and macroH2A1.2 (Kim et al., 2019). ATRX
can bind both of these isoforms which are found at telomeres and involved in the alternative
lengthening of telomeres pathway.
1.4. Alternative Lengthening of Telomeres
ATRX loss is a key feature of the Alternative Lengthening of Telomeres (ALT) pathway.
ALT is a mechanism for cancer cells to extend their telomeres without utilizing telomerase. It is
thought to use homology-directed recombination (HDR), using telomeres as templates for other
6

telomeres to lengthen. This process is associated with genome instability, micronuclei, and G2/M
checkpoint issues as well as DNA repair deficiency (Lovejoy et al., 2012). While ATRX loss
alone typically isn’t enough for ALT to occur, most cell lines utilizing the ALT pathway have
lost ATRX (Brosnan-Cashman et al., 2018). Much work is being done to understand why ATRX
loss is so prevalent in cells undergoing ALT. A few suggested mechanisms investigate the
requirement of macroH2A1 (Kim et al., 2019; Ramamoorthy and Smith, 2015), the requirement
of TERRA (Chu et al., 2017; Flynn et al., 2015) and overall telomere cohesion (Clynes et al.,
2015).
As discussed above, macroH2A1.1 and macroH2A1.2 can bind ATRX, both of which are
incorporated at telomeres. When ATRX is lost, macroH2A1.1 is no longer binding ATRX, and
so has availability for other proteins to bind. In this study, it was found that macroH2A1.1 binds
tankeryase1, which helps keep sister chromatid telomeres together. If ATRX is reintroduced,
telomeres are able to perform HDR with any other telomere and can lead to excessive
recombination and telomeric instability (Ramamoorthy and Smith, 2015). This suggests that
ATRX loss is needed for cell survival when ALT is occurring.
While Ramamoorthy and Smith identified that ATRX loss lead to increase telomere sister
chromatid binding through tankerayse1, Lovejoy and others found that ATRX loss actually
decreases telomere cohesion. In this study, it was found that ATRX is needed for telomere
cohesion, and when lost this is decreased allowing for increased interactions between non sister
chromatids (Lovejoy et al., 2020). Further work needs to be done to further understand telomere
cohesion in ATRX deficient cells.
MacroH2A1.2 is thought to act in independently from macroH2A1.1 When ATRX is
lost, macroH2A1.2 levels decrease at telomeres during replication stress (hydroxyurea
7

treatment). This is needed for double strand breaks to occur and allows for ALT. Interestingly,
restoration of macroH2A1.2 after the transient depletion is also required for HDR to occur (Kim
et al., 2019). This suggests that ATRX loss allows for the macroH2A1.2 cycling required for the
ALT pathway to successfully be performed at telomeres.
Another hypothesis for the relationship between ATRX and ALT involves the long
noncoding RNAs TERRA (Telomeric Repeat-containing RNAs). TERRA binds to telomeres and
around the genome and seems to work antagonistically of ATRX, as increases in ATRX levels
leads to decreases in TERRA levels (Chu et al., 2017; Flynn et al., 2015; Goldberg et al., 2010).
When TERRA levels increase, TERRA binds and inhibits telomerase. This then requires ALT
for cell proliferation, as telomerase is no longer functioning (Chu et al., 2017). Increases in
TERRA also can lead to increases in RPA levels at telomeres which helps promote strand
exchange and the ALT process (Flynn et al., 2015).
An additional mechanism by which ATRX loss can mediate ALT is through increased
replication stress at telomeres. In this mechanism the lack of H3.3 incorporation at telomeres
leads to an increase in secondary structures such as G-quadruplexes (see Chapter 1.7). These
structures lead to an increase in replication fork stalling, which requires repair through
homologous recombination. This repair uses the sister telomere as a template, initiating the ALT
pathway (Clynes et al., 2015).
There are many different avenues of exploration in the study of Alternative Lengthening
of Telomeres pathway. While ATRX deficiency is known to be a crucial component for ALT to
occur, there are many hypotheses for why this is the case. Overall, ATRX loss leads to an altered
chromatin state that allows for increased prevalence of ALT. This can be due in part to the

8

overlapping mechanisms of telomere cohesion, macroH2A1.1/2 deposition, TERRA
upregulation and increases in DNA breaks at telomeres.
1.5. Role in DNA repair
As DNA repair is an integral process in the ALT pathway, ATRX has also been studied for
its role in the DNA repair process. There has been evidence for ATRX’s role in homologous
recombination and nonhomologous end joining when studying genome-wide repair defects as
well as specific telomere-based studies. More work needs to be done in this field to validate
these reports as well as to further explore ATRX’s direct role in these mechanisms.
There is some evidence of ATRX’s role in nonhomologous end joining (NHEJ). NHEJ is a
template-free joining of DNA double strand breaks. In this pathway, the proteins Ku70 and Ku80
bind around the broken ends of DNA and recruit the DNA-dependent protein kinase catalytic
subunit (DNA-PKcs) (Jette and Lees-Miller, 2015). This leads to end processing and the ligation
of the DNA ends by XRCC4 and Ligase IV (Shibata and Jeggo, 2014).
In one study, a GBM mouse model was created by knocking down ATRX as well as p53 and
overexpression of NRAS. These tumors were found to have increased microsatellite instability,
ALT characteristics, and decreased NHEJ through a luciferase reporter assay and pDNA-PKcs
staining. Additionally, these cells were found to be sensitive to high doses (10-30Gy) of radiation
and other DNA damaging agents that cause double strand breaks (Koschmann et al., 2016).
While much of this data could also lead to other pathways of repair, it is interesting to suggest a
role for ATRX in NHEJ. Further work is needed to validate these findings and characterize a
mechanism for this role.
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ATRX is also thought to have a role in homologous recombination (HR). Homologous
recombination requires the recognition of a template strand with homology to the broken strand.
In this pathway, DNA is resected to form single stranded regions of DNA, where Replication
Protein A (RPA) can bind. RPA helps to prevent secondary structure formation in the single
stranded DNA (ssDNA). Through different mediator proteins, such as BRCA2, the protein
Rad51 is targeted to the ssDNA to form filaments. These filaments search for homology in
another region of the DNA, and then lead to strand invasion. Through one of multiple subpathways, new DNA is synthesized based on the homologous template, and the DNA is repaired
(Heyer et al., 2010)
ATRX has been thought to be involved in multiple steps of this pathway. In one study,
ATRX is found to bind FANCD2 (a recruiter of HR proteins and important for Fanconi Anemia
inter-strand cross link repair) through immunoprecipitation. It is hypothesized that ATRX,
DAXX, FANCD2 and the MRN complex (see Chapter 1.6) all bind in a super complex that
incorporates histones H3.3 and H3.1. This then leads to HR-mediated replication fork restart.
Overall homologous recombination levels are seen to be decreased with ATRX knockout and
siRNA to ATRX (Raghunandan et al., 2019). While how this super complex would function is
unclear, it is an interesting hypothesis that could be further studied.
Another study looks further along the HR pathway to synthesis of DNA repair. This report
found that ATRX acts later in the HR pathway as changes in RAD51 foci were not seen with
ATRX loss. However overall synthesis after damage such as radiation (measured by BrdU foci)
was reduced. ATRX was also found to interact with DNA repair synthesis machinery and enable
long-patch DNA repair synthesis. It was hypothesized that the incorporation of H3.3 during
repair synthesis is important for successful DNA repair synthesis (Juhász et al., 2018).
10

While there are multiple studies looking at ATRX’s role in NHEJ and HR, more work is
needed to fully elucidate this mechanism. Since many factors overlap between DNA repair and
replication, especially with DNA repair synthesis, much of this evidence also supports a role in
DNA replication.
1.6. Role in DNA replication
DNA replication is a crucial function for cell proliferation. Movement of the replication fork
throughout the genome requires precise timing and recruitment of many different factors. When
this process is slowed or stalled this is referred to as replication stress. This can be caused by
multiple factors, such as depletion of the nucleotide pool and legions in the path of the
replication fork caused by DNA damage or DNA secondary structures (such as G-quadruplex)
(Kotsantis et al., 2018).
One important factor in resection of a stalled fork is the MRN complex. The MRN complex
is made of three different proteins, MRE11, RAD50 and NBS1. MRE11 is a nuclease, NBS1
signals for additional repair factors and RAD50 unwinds DNA. Together MRN complex can
degrade a stalled fork and allow for replication restart (Lamarche et al., 2010).
Multiple studies show that ATRX can bind the MRN complex (Clynes et al., 2015; Huh et
al., 2016; Leung et al., 2013). Without ATRX there is an increase in degradation of the
replication fork by MRE11 (Huh et al., 2016). Others have shown that ATRX loss leads to an
increased in stalled forks and longer time in S phase (Leung et al., 2013). Some of these studies
suggest that increased G-quadruplex legions (see Chapter 1.7) are leading to these stalled forks
(Clynes et al., 2015; Huh et al., 2016).
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Additionally, since replication stress can lead to double strand breaks and homologous
recombination, many of the factors are also present at the replication fork (Kolinjivadi et al.,
2017). DNA legions can become double strand breaks as they are attempted to be replicated, and
so increases in these legions could be causing both DNA repair defects and replication stress.
While more work needs to be done to elucidate these the mechanism, ATRX seems to have an
important role in DNA replication and repair, which could be exploited therapeutically.
1.7. ATRX drug sensitivities
As ATRX is mutated frequently in cancers (see Chapter 1.2) and so there have been multiple
studies to identify drug sensitives specific to ATRX deficiency. There is currently evidence for
sensitivity to inhibitors to ATR (Flynn et al., 2015), Pol1(Udugama et al., 2018), Wee1 (Liang et
al., 2019), PARP (Huh et al., 2016; Juhász et al., 2018), and G-quadruplexes (Clynes et al., 2015;
Wang et al., 2019) as well as DNA damaging agents such as radiation and chemotherapies
(Koschmann et al., 2016; Leung et al., 2013).
Many of these drug targets require further characterization to validate these different drugs as
potential therapeutic options. For example, Wee1 was found as a potential hit in a CRISPR
screen, and had small but consistent differences between WT and ATRX knockout cells (Liang
et al., 2019). ATR inhibitor was shown to be a potential sensitizer for ALT cells, which have
more than just ATRX loss, due to increases in TERRA levels leading to more ATR activation at
telomeres (see Chapter 1.4) (Flynn et al., 2015). Decrease in rDNA copy numbers from ATRX
loss can lead to sensitivity to inhibition of RNA polymerase, Pol1 (Udugama et al., 2018).
Additionally, Koschmann found sensitivity to DNA double strand breaks created by
Doxorubicin, Topotecan, Irinotecan and Radiation in their cell model, but similar sensitivity was
not seen by Leung et al (Koschmann et al., 2016; Leung et al., 2013). All of these disparate
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results of drug sensitivities show the importance of a robust comparison of these compounds in
an ATRX KO model cell line.
An interesting drug target in ATRX KO cells is G-quadruplexes. G-quadruplex is a DNA
secondary structure that occurs in GC rich regions. This structure, seen in Figure 1.4, uses
hoogsteen interactions to allow stacking of sets of 4 guanines binding in a plane (Weldon et al.,
2016). This structure can occur in multiple areas of the genome, including telomeres, and can
cause replication stress (Clynes et al., 2015; Hänsel-Hertsch et al., 2016; Wang et al., 2019;
Zimmer et al., 2016). ATRX has been found to bind to G-quadruplexes (Law et al., 2010), and is
known to be located at these GC rich regions, such as telomeres (Clynes et al., 2015). Clynes
hypothesizes that the deposition of H3.3 at telomeres helps prevent double strand breaks at
telomeres. Stabilization of G-quadruplex will cause the greater number of G-quadruplexes in
ATRX KO cells to overwhelm the cell, leading to cell death. While some breaks are potentially
needed for ALT (see Chapter 1.4), too many can become dangerous for the cell (Clynes et al.,
2015). Additionally, Wang et al also shows sensitivity to the G-quadruplex stabilizer CX-3543 in
shATRX cells, which have increased G-quadruplex levels. They showed that this sensitivity
promotes replication stress, as this structure is difficult for the replisome to move through.
Additionally, the effect with this stabilizer can be enhanced in ATRX KO cells with a DNA
damaging agent causing double strand breaks or replication stress (Wang et al., 2019). Overall,
G-quadruplex stabilization seems to be a very interesting avenue for further research in ATRX
KO cells.
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Figure 1.4: G-quadruplex structure comparison to normal helix.
A) Hoogsteen base pairing allowing for 4 guanine molecules to be bound and stabilized
by magnesium. B) The stacking of multiple 4 guanine structures to form the Gquadruplex. C) Watson crick base pairing between guanine (left) and cytosine (right). D)
Typical DNA helix without G-quadruplex. Image from (Weldon et al., 2016)

Some preliminary work has also been done to explore PARP inhibitor (PARPi) sensitivity in
ATRX deficient cells. Poly (ADP-ribose) polymerase (PARP) have been widely studied in DNA
repair, especially after it was discovered that their inhibition leads to decreased cell survival in
BRCA mutant cells (Bryant et al., 2005). There are many questions in the field to understand the
mechanism of this sensitivity, from PARP trapping to increased replication speeds (MayaMendoza et al., 2018; Murai et al., 2012; Panzarino et al., 2020; Zandarashvili et al., 2020).
Many different cancer mutations have been suggested to lead to PARP inhibitor (PARPi)
sensitivity and is a very popular target in the DNA repair field (González-Billalabeitia et al.,
2014; Johnson et al., 2011; Stewart et al., 2014; Sulkowski et al., 2017; Turner et al., 2008).
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ATRX deficiency has had minimal analysis in the field of PARP inhibition, despite ATRX
loss’s known potential for DNA repair defects. While this has been suggested in a few papers, it
has not been robustly explored (Huh et al., 2016; Juhász et al., 2018). Huh and others identified
PARPi sensitivity in their Hela cells with and without siATRX using a lesser known PARP
inhibitor PJ-34. However it seems that the siATRX was fairly toxic without PARP inhibitor and
so more work would be needed to explore this other model systems (Huh et al., 2016). Juhász
and others focused on ATRX role in DNA repair synthesis (see Chapter 1.5). They showed
sensitivty to PARP inhibitor in Hela cells to support a homolgous recombination deficiency, but
did not investigate any mechansim of PARPi action in these cells (Juhász et al., 2018). Much
more work could be done to further explore this interaction.
1.8. ATRX and IDH1
As discussed above in Chapter 1.2, ATRX loss and IDH1 R132H are frequently seen
together in tumors. Despite this, little work has been done to understand why this occurs and how
this can be exploited therapeutically. There are only a few papers that study both IDH1 mutation
and ATRX mutation in the same cell line and more needs to be done to further explore this
combination of mutations (Mukherjee et al., 2018; Núñez et al., 2019).
Isocitrate dehydrogenase (IDH1) is an enzyme in the citric acid cycle that converts isocitrate
to α-ketoglutarate. When it was first identified as a common mutation in glioblastoma, with 12%
of a cohort having the mutation, it was shown that these patients have increased overall survival
compared to patients with wildtype IDH1. Additionally nearly every patient had a mutation at
the same residue R132, a highly conserved residue in the IDH1 protein (Parsons et al., 2008). It
was later shown that this mutation gives a new function to IDH1, converting its original product
α-ketoglutarate to a new molecule, 2-hydroxyglutarate. This creates a nearly 100-fold increase in
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the 2-hydroxyglutarate levels in the cell and surrounding media (Dang et al., 2009). These
extremely high 2-hydroxyglutarate levels lead to inhibition of α-ketoglutarate dependent
dioxygenases, which have a variety of functions throughout the cell (Xu et al., 2011). One
inhibited dioxygenase is KDM4A, a histone demethylase that acts on H3K9 methylation. Not
only is H3K9 methylation used to mark heterochromatin (see Chapter 1.3), it is also used for
transient signaling of double strand breaks. With increased levels of H3K9 methylation, DNA
repair factors are not able to properly target a DNA double strand break, leading to decreased
homologous recombination (Sulkowski et al., 2020). This then leads to a “BRCAness”
phenotype that causes cells with increased 2-hydroxyglutarate levels to be sensitive to PARP
inhibitors. It is also thought that patients with IDH1 mutant tumors have greater overall survival
due to this increased sensitivity to DNA damage (Sulkowski et al., 2017; Wang et al., 2020).
However, there is some work that contradicts this hypothesis. Núñez et al. finds that R132H
mutation leads to an increase in the DNA damage response through epigenetic changes that
upregulate HR genes. This leads to elevated HR levels and radiation resistance. Interestingly, this
cell model also knocked down ATRX and overexpressed NRAS, and the authors argued that the
combination with ATRX loss leads to this opposite result (Núñez et al., 2019). This shows the
importance of further exploring the double mutation of IDH1 and ATRX, to validate this work
and better understand these tumors.
Another study that looks at the combination of IDH1 R132H and ATRX instead investigates
in role in Alternative Lengthening of Telomeres pathway (see Chapter 1.4) instead of overall
DNA repair. Mukherjee et al. show that epigenetic changes in R132H mutant tumors lead to the
downregulation of telomere capping protein RAP1 and the NHEJ factor XRCC1, increasing their
ability for the homology directed repair used in ALT to occur. They found that both loss of
16

ATRX and overexpression of R132H mutant IDH1 was enough to cause the ALT phenotype,
despite neither mutation alone allowing this to occur. This provides another mechanism that
could explain the frequent co-occurrence of ATRX and IDH1 mutation.
1.9. Conclusions
ATRX is an important chromatin modifier that has been implicated in multiple DNA repair
and regulation pathways. While much more work can be done to clarify its many activities
within the cell, it is clearly important for telomeric and overall genomic stability. As is it mutated
frequently in glioma and other cancers, further study of ATRX as a biomarker for potential
therapeutics is critical for the successful treatment of patients with these mutations.
In this study, I developed three different cell lines with ATRX KO in cell lines relevant to
glioma research. I then characterized the DNA repair capacity in these cells and found increases
in replication stress and potential for decreased homologous recombination. Furthermore, I
identified through CRISPR screen the importance of other chromatin modifiers in the survival of
ATRX KO cells. I also determined that ATRX KO can lead to PARP inhibitor sensitivity, due to
increased ATR activation in these cells. This further suggests the increased replication stress in
ATRX mutant cells. I also showed that these cells have equal sensitivity to PARP inhibitor
regardless of IDH1 status, suggesting overlapping mechanisms of DNA repair defect that can be
explored further.
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2. Materials and Methods
Antibodies and Reagents
Antibodies: ATRX: Millipore Sigma 39F MABE1798 and Santa Cruz sc-55584 were used
1:1000 overnight in 1X TBST after 5% milk block for western blot, pChk1: CST 2341 was used
at 1:500 overnight at 5% BSA in 1X TBST . Drugs were purchased through Selleckchem.
Cell Culture
All cell lines were grown in DMEM with 10% FBS. For siRNA experiments, siRNAs were
purchased from Dharmacon (siATRX (Dharmacon J-006524-05), XPC (L-016040-00), KDM2A
(L-012458-02), CLK2 (L-004801-00), UHRF1(L-006977-00), XRCC3 (L-012067-00)) were
transfected into cells using Life Technologies Lipofectamine RNAiMax (13778) and imaged 96
hours later or seeded for growth rate experiments 72 hours later. IDH1 R132H overexpression
construct from Addgene (66803).
Clonogenic Survival Assay
Cells were seeded at a three-fold dilution between 9000 and 37 cells per well of a 6 well plate
in triplicate and incubated in multiple drug concentrations for 14 days. Plates were washed with
PBS, stained with crystal violet for 1 hour, and quantified.
CRISPR knockout
To create the CRISPR knockout cell line, a guide to exon 9: (5’AAATGCATTCTACGCAACCT-3’) was cloned into the MLM3636 plasmid (Addgene 43860).
This plasmid along with a Cas9 plasmid were nucleofected into the cells and after at least 72
hours, successful Cas9 cleaving was validated using a T7 endonuclease assay. Cells were then
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diluted to single cells into nine 96-well plates. Wells were then screened for colonies and replica
plated to 96-well plates for imaging (Greiner screenstar 655866), and further passaged. Imaging
plates were stained using the immunofluorescence protocol below. Cells with diminished ATRX
foci were then chosen for further testing.
CRISPR Screen
To perform the CRISPR screen, cells were seeded in 15cm plates and transduced with
CRISPR library (from Gupta Lab). Cells were selected in puromycin for three days and samples
harvested periodically over 14 days. Genomic DNA was purified from samples and region with
CRISPR insertion amplified. Each amplified PCR product was barcoded for each condition, and
then pooled and sent for next generation sequencing (Genohub). Results were analyzed by Dr.
Gregory Breuer to give beta scores for each gene.
Growth Rate
For determination of growth rate, cells were seeded at low densities (1000 or 2000 cells per
well). In 1 column of a 96-well plate for 1 plate per day of study (typically 5 plates, 6, 24, 48, 72,
96 hours). Each plate was analyzed using short term viability assay protocol below.
Immunofluorescence
For immunofluorescence assays, cells were seeded in chamber slides (Millipore
PEZGS0816) or 96 well plates (Greiner screenstar 655866). Cells were treated as indicated. For
cyclin A (Santa cruz B-8 sc-271682), ATRX (Millipore), H2AX (Millipore 05-636) and 53BP1
(Novus NB100-904), cells were fixed in 4% PFA, 0.02% Triton in PBS for 15 minutes. Cells
were then permeabilized/blocked for 1 hour in 5% BSA, 0.5% Triton in PBS and in primary
overnight at 1:500 in blocking solution. Secondary (Alexa Fluor 647) was diluted 1:1000 for 1
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hour. For pRPA32 S33 (Bethyl A300-246A) protocol was used as previous (Shiotani et al.,
2013). Foci were analyzed using the Focinator (Oeck et al., 2017).
Neutral Comet Assay
Assay performed with manufactures protocol (Trevigen). In brief, cells were trypsinized and
resuspended in LM Agarose (Trevigen). Slide was then left to dry, followed by lysis and
incubated in neutral electrophoresis buffer at 21V for 45mins in the CometAssay Electrophoresis
System (Trevigen). DNA was then precipitated and slides were dried overnight. After stained the
following day with SYBR Gold; slides were then imaged on EVOS FL microscope (Advanced
Microscopy Group), with 15 fields of view per replicate (greater than 100 cells). OpenComet
was used to quantified comet tail moment (Gyori et al., 2014). Experiment performed in
triplicate and data are means ± SEM.
Plasmid Reporter Assay
Cells were seeded at 40-60,000 cells in 24 well plate. Cells were transfected with 1µg of
linearized Lux4 or PGL3 plasmid (from Glazer lab) and 250ng of Renilla control plasmid. After
24 (PGL3) or 48 (Lux4) hours, cells were harvested, lysed and analyzed with Promega DualLuciferase Reporter Assay System (Promega E1910).
Sequencing
Genomic DNA was purified from cells and CRISPR region was amplified. TOPO reaction
was performed using TOPO TA cloning kit (Thermo Fisher 450071) and transformed into DH5α
cells. DNA was amplified through colony PCR using SapphireAmp fast PCR (Takara Bio
RR350), and PCR cleanup was performed with ExoSAP-IT™ (Applied Biosystems 75001).
Sequencing was performed by the Yale Keck Biotechnology Resource Laboratory.
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Short Term Viability Assay
Cells were plated at 2,000 cells per well of a 96-well plate. The following day cells were
treated with various concentrations of drug as indicated. 96 hours after of drug treatment, cells
were washed in 1X PBS, fixed in 4% formaldehyde, and stained with Hoechst at 1 µg/ml. Plates
were imaged on a Cytation 3 (BioTek) and cells were counted using CellProfiler
(http://cellprofiler.org/). For synergy assays, synergy was calculated using the Loewe method
through Combenefit (Di Veroli et al., 2016).
Statistics
Student 2 tailed T test was performed to compare groups using GraphPad Prism unless
otherwise described. Asterisks indicate levels of significance/p value (*≤0.05, **≤0.01,***
≤0.001,**** ≤0.0001). Error bars indicate standard deviation.
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3. Creation of ATRX knockout model
Parts of this chapter are adapted from work in publication:
Garbarino, J., Eckorate J., Jensen, R., and Bindra, R.. Loss of ATRX confers DNA repair
defects and PARP inhibitor Sensitivity. Translational Oncology (in revision) 2021.
3.1. Introduction
When looking to characterize a specific protein, it is important to identify a relevant model
cell line. In this case, I wanted to focus on identifying ATRX’s role in brain cancers, and so
focused on choosing models that are related to this system. The goal was to create an isogenic
pair of cell lines to identify how ATRX loss alone impacts DNA repair and therefore changes
sensitivity to different DNA damaging agents and repair inhibitors.
For this reason, I focused my efforts on the glioma cell lines LN229 and U87 as well as an
immortalized astrocyte line. Each of these cell lines express ATRX, and have been used to model
gliomas previously (Cai et al., 2015; Jackson et al., 2019; Sulkowski et al., 2020; Wang et al.,
2019) and so would be good options for future characterization of this mutation.
I chose to use CRISPR/Cas9 to create the ATRX knockout cell lines. CRISPR (Clustered
Regular Interspersed Short Palindromic Repeats)/Cas9 is a tool developed based on bacterial
immunity. The Cas9 enzyme has ability to specifically target a region of the genome given to it
as an RNA sequence, for cleavage. While this is used in bacteria to defend against viral DNA, it
has now been repurposed for targeting the genomes of human cells. By expressing Cas9 and an
RNA sequence of interest in cells, Cas9 can specifically cut genomic DNA and through DNA
repair lead to the loss of that proteins expression. This relatively simple method has
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revolutionized genomic editing, both for potential therapeutics and as a tool for research (Ahmad
et al., 2018).
Creating this RNA sequence is an important component to utilizing the CRISPR/Cas9
system. These RNAs, called guide RNAs (gRNA) are what determine the exact place Cas9 will
cut. For ATRX loss, there is no specific hotspot mutation in glioma, and mutation could be
induced in any part of the genomic sequence. However, different sequences will have different
affects, both in their ability to cut at the region of interest and to minimize chances of cutting in
other locations. These have been quantified through on- and off-target scores.
On-target scores determine the ability of Cas9 to cleave DNA at the genomic loci. While all
gRNAs need to be targeted to a 5′-NGG protospacer adjacent motif (PAM) site for cleavage to
occur, the surrounding region can also dictate how efficient DNA cleavage will be. Through
testing of over a thousand gRNAs, a model was able to be created by Doench and others to
determine how successfully a gRNA will lead Cas9 to cleave (Doench et al., 2016). This model
has been utilized to create an on-target score, which on a scale of 0-100 (higher indicates better
cleavage) rates the ability of cleavage at a given site.
As important as an on-target score, the off-target score determines where else in the genome
Cas9 could cleave given a specific gRNA. A similar model to off target score was created by the
Zhang lab, allowing for a predicted score of how specific a gRNA will be (Hsu et al., 2013). This
score, also a scale of 0-100, rates more specific gRNAs with numbers closer to 100. This allows
a user to look for both a high off-target and on-target score as a predictor of successful cleavage.
These factors were utilized in the design of my CRISPR/Cas9 ATRX knockout clones. With
these designs, I created three different knockout cell lines, LN229, U87 and immortalized
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astrocytes to use for these experiments. During this process, I also developed a robust CRISPR
knockout screening platform to allow me to readily analyze hundreds of clones. Identifying a
successful method for ATRX KO creation was an important foundation for understanding the
role of ATRX loss in glioma.
3.2. LN229 knockout creation through western blot screening:
To model the ATRX mutation, I first created 5 CRISPR gRNAs (Table 3.1). These gRNAs
were chosen to be early in the ATRX sequence (exon 1-3) to ensure that no partially functional
protein would be created.

gRNA Exon

Sequence

1
2
3
4

2
2
3
2

5’-CCACGACTTGCAATGAATCA-3’
5’-TGAAAGCAAGTTGAATACAT-3’
5’-TGGAAGTAACTCTGATATGA-3’
5’-TGCACACTCATCAGAAGAAT-3’

5

1

5’-ACATGACCGCTGAGCCCATG-3’

On
Off
Target Target
Score Score
63
87
49
43
39
58
54
56
62

41

Table 3.1: CRISPR gRNA designs
Guides were designed to PAM sites in exons 1-3 and were chosen as those with the highest on
and off target scores in this region.

These gRNAs had the highest on and off target cutting scores of this region. Each gRNA
was then nucleofected along with Cas9 into the LN229 cell line. In this technique, Cas9 is only
be transiently expressed, and not able to create further non-specific cuts over time. I then
performed a T7 endonuclease assay which detects mismatches in DNA. After amplifying the
genomic region surrounding the CRISPR gRNA site, the DNA is melted and reannealed. If
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successful CRISPR cutting has led to mutation in a portion of the DNA, then these mutant DNA
copies will mostly bind to the more prevalent wild-type copies. The T7 endonuclease will then
cleave the DNA at the mismatch, which can be identified as lower bands on the gel. The amount
of cleaved DNA visualized can qualitatively show how much cutting occurred and ensure that a
high enough proportion of the population had successful cutting to be screened for effectively.
Of these gRNAs, gRNA 2 had the most successful cleavage (Figure 3.1).

Mock

gRNA Mock
2

gRNA
5

Figure 3.1: Successful cleavage with Cas9 and gRNA 2.
After transfection with Cas9 and gRNA 2, 5 or mock transfection, T7 endonuclease assay was
performed on PCR amplified region of exon 2 of ATRX. Red arrows indicate bands created
from mismatch at CRISPR cut site. For gRNA 5, while band was visualized, this band was
also seen in the mock treatment and not specific to CRISPR cleavage.
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Once this guide was selected as most successful, I diluted the cells to single cell colonies
in 96 well plates. No antibiotic selection is used in this system and so many clones need to be
analyzed. I, with assistance from an undergraduate researcher Jillian Eckorate, screened just over
200 LN229 clones through western blotting. Through this screening two clones were found to
have no protein expression, 87 and 180 (Figure 3.2). This indicates that the efficiency for
creating a CRISPR knockout using these cells and guide 2 was approximately 1%. After
sequencing (see Chapter 4.2, Figure 4.1) it was found that these clones were identical and must
have been duplicated at some point in the single cell cloning process.

Figure 3.2: Representative western blots for LN229 ATRX clone screening
Western blots were performed on 200 potential ATRX knockout clones. Clones 87 and 180
were chosen for further analysis.
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3.3. Development of foci screening pipeline
Screening the LN229 ATRX KO clones was a long, arduous process and required managing
the expansion of many clones. To streamline this process, I began to develop a 96-well plate
format for clone screening. I found from work initially characterizing cells with siATRX that
ATRX foci are easily visualized through immunofluorescence in a 96-well plate imager (Figure
3.3B). This method was demonstrably improved to the traditional western blot screen by scaling
up the screening process to 60 clones per 96 well plate and allowing for each plate to be read
easily by an automatic plate imager.
In this method (Figure 3.3A), after initial dilution of approximately 1 cell per well of a 96
well plate, colonies that came from 1 cell are then moved into the inner 60 wells of a new 96
well plate. Inner 60 are used because the plate imager cannot read edge wells at 40X
magnification. This plate is then split into 2, 1 traditional cell culture 96 well plate, and one
imaging plate. After staining for ATRX, automatic imaging is performed to detect the ATRX
foci. I then can quickly look through the images for those with low ATRX foci. Clones of
potential interest can then be chosen off the replica plate for expansion and further
characterization by western blot. This process was able to be utilized for the creation of new
ATRX CRISPR knockout cell lines and allowed for a much more streamlined approach to
screening.
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Figure 3.3: Immunofluorescence screening pipeline successful in identifying ATRX
CRISPR knockout cells.
A) Schematic of immunofluorescence screening pipeline for CRISPR clones. B)
Validation of immunofluorescence ATRX foci 96 hours after siRNA transfection.
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3.4. U87 clone creation
After the low efficiency of gRNA 2 in the LN229s, I created new gRNAs in later exons of
ATRX. Despite being later in the protein, they have much higher on and off target scores (Table
3.2). While exon 9 is further into the protein, ATRX is a large protein with 36 exons. Despite
being several exons into the genomic sequence, this is still very early into the protein and
importantly occurs before the completion of the first domain (Figure 3.4). This minimizes the
chances of a partial formed protein expressing and binding to DNA, despite full-length
expression not occurring.

gRNA

Exon

Sequence

On
Target

Off
Target

A

9

5’-AAATGCATTCTACGCAACCT-3’

70

87

B

9

5’-AGAACAAATAAAAGTACCGG-3’

72

74

C

9

5’-ACTCTTATTCCGCACTAATT-3’

64

74

Table 3.2: Improved guide RNAs to exon 9 for ATRX KO
Guides were designed to PAM sites from exons 1-15 and had the highest on and off
target scores in this region.
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Figure 3.4: gRNAs targeted to beginning of ATRX protein.
gRNAs 1-5 were designed to be in the first three exons which are very early in the ATRX gene.
While the newly designed gRNAs are further down the genetic sequence, ATRX is a large
protein and so these are still at the beginning of the ATRX protein. These gRNAs are also
targeted to the ADD domain.

I then transfected each gRNA into the U87s as done in the LN229s and performed a T7
endonuclease assay with new PCR products from exon 9. gRNA A was found to be the most
successful guide, and so was used for further analysis (Figure 3.6).
After dilution, instead of expanding clones to 6 well dishes for western blot, the foci
pipeline described (Figure 3.3A) was used to screen U87 clones. Using this pipeline allowed for
the screening of 120 clones at the 96 well level, saving the time of clone expansion and
numerous western blots. Of these 5 had evidence of loss of ATRX expression (Figure 3.5). When
validating through western blot 2 of the 5 clones were found to be ATRX negative. This
increased the efficiency of the screen to 1.7%, but more importantly shortened the timespan to
screen these clones considerably.
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Guide
A

Guide
C

Ctrl

Ctrl
no T7

Figure 3.6: Successful cleavage with Cas9 and gRNA A in U87.
After transfection with Cas9 and gRNA A or C, or mock transfection, T7 endonuclease
assay was performed on PCR amplified region of exon 9 of ATRX. gRNA C was
unsuccessful in targeting Cas9 for cutting, while gRNA A was successful and used for
further experiments.

ATRX

vinculin
Figure 3.5: Utilization of immunofluorescence foci pipeline for U87 ATRX KO.
Representation of screen for U87 Parental clones. Potential hits labelled in green
were expanded for further analysis. Representative western blots shown below of
selected clones.
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3.5. U87 R132H Clone Creation Attempt
While it is important to look at ATRX knockout alone, it is also very interesting to determine
how it interacts with other mutations it commonly co-occurs with, such as IDH1 R132H. As a
U87 R132H model already existed in the Bindra Lab, adding the ATRX KO seemed like an
excellent way to characterize this double mutation.
I transfected U87 IDH1 mutant cells with Cas9 and the same gRNA A used in the U87
parental cells. I found that my efficiency of editing, determined by T7 endonuclease assay,
seemed to be much lower than my U87 parental cell knockout, as the gel needed to be exposed
much longer to see the band indicating Cas9 cleavage (Figure 3.7). Since cutting was seen I
proceeded forward with growing single cell clones for screening as I could increase my number
of clones screened more readily with my foci screening platform.

Ctrl
- T7

Ctrl

Guide
A

Figure 3.7: Successful cleavage with Cas9 and gRNA A in U87 R132H cells.
After transfection with Cas9 and gRNA A or C, or mock transfection, T7 endonuclease
assay was performed on PCR amplified region of exon 9 of ATRX. Red indicates
oversaturation of signal for uncut bands. While gRNA A was successful, the efficiency
of cleavage was much lower than with the parental U87 cell line (Figure 3.6).
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I screened approximately 240 clones via immunofluorescence and found only 4 clones that
seemed promising (Figure 3.8). However, of the 4, only 1 was able to effectively grow, but was
found to still retain ATRX expression through western blot (data not shown). The lack of
successful clones could be due to the deficiencies already present in the IDH1 mutated cells,
such as their high levels of the oncometabolite 2-hydroxygluarate (see Chapter 1.8). Because of
this, U87 R132H cells were not used as a cell line model.

Figure 3.8: Schematic of foci platform results for U87 R132H screen.
Potential hits labelled in green were attempted to be expanded for further analysis. No
hits were successfully expanded that have ATRX knockout.
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3.6. Immortalized Astrocyte clone screening
In addition to using glioma cell lines, I also wanted to compare in a cell line that had less
background mutations but was still relevant to the brain cancer setting. I chose immortalized
astrocytes as this model. Immortalized astrocytes are normal human astrocytes with only a few
mutations that keep them growing in cell culture (Wang et al., 2019).
The same gRNA A from Table 3.2 was used and successful cleavage at the cut site was seen
using the same T7 endonuclease assay (Figure 3.9).

CtrlT7

Ctrl gRNA gRNA
A
-T7

Figure 3.9 Successful cleavage with Cas9 and gRNA A in immortalized astrocytes.
After transfection with Cas9 and gRNA A or mock transfection, T7 endonuclease
assay was performed on PCR amplified region of exon 9 of ATRX.

I then employed the foci screening platform used to screen of the U87 cell lines, this time
with increased success. With 14 clones of interest in the initial screening, nearly 6% of the clones
tested had evidence of ATRX knockout (Figure 3.10). Of these five were found to have no
ATRX expression through western blot. This could be because these cells grow more readily
from a single cell than the U87, and that they also had more efficient Cas9 cleavage. Clone 3-B7
was chosen to be used for further characterization.
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ATRX

vinculin

Figure 3.10 Utilization of immunofluorescence foci pipeline.
Representation of screen for immortalized astrocyte clones. Potential hits labelled in
green were expanded for further analysis. Representative western blots shown below of
selected clones. Clone 3B7 was chosen for further characterization.
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3.7. Discussion
CRISPR is a valuable tool for the creation of isogenic cell lines. These cell lines give the
ability to compare as similar conditions as possible, with only the gene of interest differing
between them. However, there are many important factors to the success of these CRISPR
knockout cell lines.
One important element to the creation of these cell lines, is the design of the CRISPR gRNA.
While at first I focused on ensuring the knockout location being as close to the beginning of the
protein as possible, this severely limited my options of strongly scored gRNAs. These first
gRNAs I designed were the relatively better gRNAs, but did not have very high scores when
compared to typical ideal CRISPR guide RNAs (Table 3.1 vs Table 3.2). While the gRNA I first
chose (gRNA 2) was successful, the screening of clones was a very inefficient process, probably
in part due to the low on-target score. This was why creating new guides was a crucial step to the
eventual creation of the other cell lines.
I also found that certain cell lines are more adapted to the CRISPR screening process than
others. For example, I was unable to find any U87 IDH1 R132H clones to successfully knockout
ATRX. I screened double the number of clones that was used for the U87 parental cell line, and
yet had very few potential options, nearly all of which died during attempted expansion (Figure
3.8). This suggests a biological difficulty in creating this cell line, despite the frequency of cooccurrence in tumors. While out of scope for this work, a way to determine if this was the case
would be to try to create the cell line again but in the presence of an R132H inhibitor. The
inhibitor would block 2HG production and essentially allow the cell line to behave more like
wild type until expanded and 2HG production could be allowed to continue.
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In the literature there have been two creations of this double mutant cell line (Mukherjee et
al., 2018; Núñez et al., 2019). In both, ATRX knockout/knockdown was performed first, then
IDH1 R132H overexpression. This could perhaps indicate that this order of mutation is necessary
in patients for tumor growth. This further supports the necessity of further study of the interplay
of these two mutations.
Overall, the CRISPR knockout method I chose can be inefficient, as transfection has a lower
success rate than other methods such as transduction. However, I used this method because I
wanted to ensure that Cas9 was not constitutively expressed in my cell line. As I am studying
DNA repair capacity, I wanted to ensure that Cas9 was not nonspecifically cleaving DNA, even
at low levels while my experiments were performed. I also did not want my cells to require
antibiotic selection, as this is another variable that could affect how the cells behave. This
method minimized the changes to the genome and helped create as ideal an isogenic pair as
possible for my studies.
To help increase the efficiency of using this method, I developed a foci-based screening
platform instead of screening through western blotting. This allows for many more clones to be
screened at once before expansion, which can help making up for the inefficiency of transfection
and no selection. The pipeline in its currently form relies on the fact that ATRX readily form foci
at in the absence of damage (Figure 3.3). However, this method could be utilized for other
proteins that do not form foci by instead quantifying intensity of staining. As long as proper
optimization is done to ensure that there is a difference in visualization of a protein based on
whether or not it is present, this method can be applied to many other proteins.
When utilizing all the information learned from this endeavor, many successful CRISPR
knockout models can be created. Identifying ideal guide RNAs, cell lines and screening methods
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are all important in the efficient creation of a strong model system to use for future studies. Once
model cell lines are created, many different experiments can be performed to analyze the specific
differences caused by loss of a protein, such as ATRX.
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4. Characterization of LN229 and U87 ATRX knockout
4.1. Introduction
Understanding the DNA repair capacity of the LN229 and U87 knockout cells is important
for learning how to treat these mutations in the clinic. As there are many DNA damaging agents
and repair inhibitors already used therapeutically, being able to use ATRX status as a biomarker
would be very advantageous. Since DNA repair defects can often lead to increased mutational
rate, many believe inhibiting these mutations is the solution to halting cancer growth. However,
exploiting these defects instead can be a powerful tool to kill cancer cells. By analyzing a
mutations specific DNA repair defect, inhibitors to alternative repair mechanisms can be utilized
to overwhelm the cell with DNA damage.
To identify how DNA damage is repaired in a cell, investigating the signaling components is
often a key step. This is often done through foci analysis for specific DNA repair factors. DNA
damage sites recruit many copies of repair factors that can be identified through
immunofluorescence, called foci. The number of foci at various times can be used to determine
the amount of DNA damage and repair is occurring. Two major markers of DNA damage
signaling are γH2AX and 53BP1.
γH2AX is the phosphorylation of histone H2 variant H2AX at residue serine 139. This
phosphorylation can be performed by ATR, ATM and DNA-PKcs to signal the chromatin
location of a DNA break. This is one of the earliest signals for a DNA break, and so is a great
tool to determine how many breaks are occurring throughout the genome (Kuo and Yang, 2008;
Paull et al., 2000). This signal is propagated around the region of damage to create a platform
for the recruitment of repair factors, whether homologous recombination (HR) or
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nonhomologous end joining (NHEJ) factors (Collins et al., 2020). This phosphorylation event is
now readily studied as an early stage indicator of DNA damage and can be used to compare
differences in amounts and response to damage.
53BP1 is another factor well studied in the DNA repair field. A signal downstream from
γH2AX, 53BP1 is important for pathway choice and recruitment of many other DDR factors. Its
recruitment favors nonhomologous end joining and alternative end joining (Mirza-AghazadehAttari et al., 2019; Ward et al., 2003; Xiong et al., 2015). This factor along with γH2AX can
show how much DNA damage and repair is occurring in a cell.
Another way to determine a DNA repair defect in cells is to compare the survival of cells in
the presence of DNA damaging agents and repair inhibitors. By screening different compounds,
a synthetic lethal interaction can be identified. Synthetic lethality is the concept that while
knocking out one gene (in this case ATRX) allows for cell survival as well as the independent
inhibition of another protein, but when both are lost cells are no longer able to survive. A classic
example of this is BRCA loss and PARP inhibitor sensitivity (Bryant et al., 2005). While BRCA
loss and PARP inhibitor are tolerated by cells, the combination is much more lethal than either
action alone. Since this work much has been done to understand the relationship between
BRCA1/2 and PARP, furthering knowledge of DNA repair mechanisms as well as providing a
therapeutic option for patients with BRCA mutant tumors. Finding other synthetic lethality
combinations for other cancer proteins, such as ATRX, is a promising strategy to discover other
potential treatments.
By focusing on DNA repair capacity in ATRX knockout cells, it is possible to get
mechanistic insights into the DNA repair process as well as potential therapeutic options for
patients with these mutations. With the LN229 and U87 ATRX KO cell lines I showed a
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decrease in homologous recombination and an increase in replication stress. While outside
factors may have led to only minor differences in drug screen sensitivities, future study could
widen these differences and allow for better options for further study.
4.2. LN229 and U87 ATRX KO Clone Validation
LN229 ATRX knockout was validated through three methods: western blot,
immunofluorescence, and sequencing. As seen in Figure 4.1A-B, there is no detectable ATRX
expression in these cells by western blot or through immunofluorescence staining.
Since there are multiple copies of ATRX in LN229, I performed TOPO cloning to amplify
and sequence genomic PCR products individually. Out of 65 products sequenced, there were 22
copies of a 136 base pair insertion and 43 copies of a 1 base pair deletion (Figure 4.1C). The
uneven amounts of each sequence type could be due to different integration rate of the different
sized PCR products.
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Figure 4.1: LN229 ATRX knockout clone validation
A) Western blot showing ATRX levels in WT vs ATRX knockout (KO) clone. B)
Immunofluorescence staining for ATRX in WT and KO cell lines. Cells were stained with
Hoescht dye for nuclear staining as well as ATRX antibody C) Sequencing data from the
ATRX KO clone. Mutation is shown in red. While allele 1 has a 1 base pair deletion, allele 2
has a 136 base pair insertion. Insertion sequence is listed below so alignments between KO
alleles and WT can be compared.
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While validating ATRX KO, I noticed that there were typically more cells in my ATRX
knockout plates than in the parental LN229 ones. To quantify this difference, I seeded equal
numbers of both cell lines and tracked their growth overtime. I determined that there were more
cells in the ATRX knockout wells at each time point, including the initial time point. Since this
could be due to an increase in cell adherence or initial seeding, I then repeated the experiment
using 1,000 and 2,000 cells per cell line. I found that despite having fewer cells by 24 hours,
ATRX knockout cells had more cells than the parental line by 96 hours (Figure 4.2). This
suggests that ATRX knockout cells proliferate at a higher rate than the parental cells.

G r o w t h o f U n t r e a t e d C e lls
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N u m b e r o f C e lls

30000
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0
0

50
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Figure 4.2: Growth rate of LN229 WT vs ATRX KO cells
1,000 or 2,000 cells per well were plated in multiple 96 well plates. At each time point
over 96 hours, one plate was fixed and number of cells were counted. WT counts are
shown in blues and ATRX KO cell counts are shown in greens.
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I validated the U87 ATRX KO cell lines in a similar manner. First confirmation of knockout
was shown through western blot and immunofluorescence in clone B4 and clone C9 (Figure
4.3A-B). Then TOPO sequencing was performed to attain allele sequences on both clones. For
clone C9, 13 sequences had a 26 base pair deletion and 18 sequences had a 1 base pair insertion.
Both mutations lead to a stop codon and a lack of functional protein (Figure 4.3C).
For Clone B4, while one 18 sequences contained a 2 base pair deletion, 6 sequences led to a
9 base pair deletion (Figure 4.3C). The 9 base pair deletion leads to a loss of 3 amino acids and
remains in frame for the rest of the protein. However, since there is a lack of detectable
expression, this could still be leading to lack of expression. This could occur because the
mutation deletes three amino acids in an alpha helix in the ADD domain of the protein. This
deletion could lead to misfolding and degradation of the mutant protein. Additionally, as ATRX
is located on the X chromosome, this second allele could be inactivated with the rest of the X
chromosome, leaving only the non-functional first allele to be expressed. However, since this
mutant protein could be expressed at low levels, I primarily focused my work on clone C9.
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Figure 4.3: U87 ATRX knockout clone validation
A) Western blot showing ATRX levels in WT and ATRX knockout cells for both U87
clones. B) Immunofluorescence staining for ATRX in WT and KO cell lines. Cells were
stained with Hoescht dye for nuclear staining as well as ATRX antibody C) Sequencing
data from the ATRX KO clone. Mutation is shown in red for both DNA and amino acid
sequence.
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I then began to characterize the C9 ATRX knockout cell line. These cells have a different
morphology that causes them to not form the same structures as the wild type cells (Figure 4.4B).
This leads to these cells becoming confluent on the plate with less cells present (Figure 4.4A).
This change could be due to a cloning artifact, as many of the single cell clones observed had
different morphologies regardless of ATRX status, or from ATRX loss itself.

A

B

Figure 4.4: Growth of U87 ATRX KO clone altered from WT
A) 1,000, 2,000 cells or 4,000 cells per well were plated in multiple 96 well plates. At
each time point over 96 hours, one plate was fixed and number of cells were counted.
WT counts are shown in black and ATRX KO cell counts are shown in gray. Solid line
indicates 4000 cells plated, dashed line is 2,000 cells and dotted line is 1,000. B)
Visualization of changes in morphology between WT and ATRX KO cells. Typical U87
cell clustering is abrogated in ATRX KO cells
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4.3. DNA repair capacity
After these clones were established, the next step was to determine their DNA repair
capacity. These glioma lines were characterized by their ability to perform homologous
recombination, signal for damage and propensity for double strand breaks. Overall, I found a
modest but consistent DNA repair defect in these cell lines, specifically suggesting deficiencies
with homologous recombination and increased replication stress.
The ability of these cells to repair DNA through homologous recombination or
nonhomologous end joining was investigated through a luciferase reporter assay. In this assay a
linearized plasmid is transfected into cells and repair leads to luminescence. For HR,
luminescence only occurs when a template further down on the plasmid is used to repair the
break and for NHEJ luminescence occurs if the repair causes a frame shift leading to expression
(Figure 4.5D).
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Figure 4.5: Homologous Recombination rate decreased in ATRX KO cells
A) Homologous recombination rate in LN229 cells compared between WT and ATRX
KO B) Homologous recombination rate in U87 cells with ATRX KO or IDH1 R132H
mutation compared to WT. For A) and B) Cells were analyzed 48 hours after transfection
and normalized to Renilla luciferase signal before normalization to fold change over WT.
C) Nonhomologous end joining rate in LN229s using NHEJ reporter plasmid. Cells were
analyzed 24 hours after transfection and normalized as above. D) Schematic depicting the
repair needed for luciferase to be expressed in both reporter assays.
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I have found that in both LN229 and U87 cells the reporter plasmid is unable to be repaired
by homologous recombination as readily in the ATRX KO cells as in comparison to their WT
counterparts (Figure 4.5A-B). I have also found that the LN229s have no change in the ability to
perform NHEJ repair of the transfected plasmid (Figure 4.5C). The NHEJ assay in the U87s was
too toxic to determine the luciferase rate, but U87s were able to be compared to the U87 R132H
cell line which has a known homologous recombination defect (Sulkowski et al., 2017). I see a
similar rate of homologous recombination in these two mutant cell lines (Figure 4.5C), which
suggest that ATRX KO has equivalent DNA repair defect to the IDH1 mutant cell line.
In addition to identifying changes in homologous recombination, I also wanted to investigate
increases in replication stress in the ATRX KO cells. Following evidence in the literature of
replication stress, I first looked at the effect of hydroxyurea treatment overtime (Leung et al.,
2013). I found that at 18 and 24 hours after treatment there was an increase in γH2AX foci, a
marker for DNA damage in ATRX deficient cells (Figure 4.6). To ensure that this was not due to
the cells becoming confluent faster due to their faster growth rate, I repeated this experiment
with different amounts of cells and achieved the same results (data not shown). This could
suggest that ATRX knockout cells have increased levels of replication stress, as well as the
homologous recombination defects seen above (Figure 4.5).
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Figure 4.6: LN229 ATRX KO has increased levels of γH2AX foci after HU treatment
LN229 WT and ATRX KO cells were analyzed at 1, 3, 18 and 24 hours after 1mM HU
treatment. Percentage of cells with greater than 20 γH2AX foci were quantified for each
condition. Representative image shows γH2AX levels 24 hours HU treatment.

50

Once the U87 ATRX KO cell line was created, I also investigated its response to
hydroxyurea. I found that the ATRX KO U87 cells showed similar increase in γH2AX levels
after 18-24 hours of hydroxyurea treatment to their LN229 counterparts (Figure 4.7).
Additionally, this was similarly elevated in the U87 R132H parental cell line, which has been
shown to have these increases in these foci previously at baseline (Sulkowski et al., 2017). This
suggests that there is also increased replication stress in both the U87 and LN299 ATRX KO cell
lines. Interestingly, the U87 cell line also had large increase in untreated γH2AX and 53BP1
levels. I hypothesize that ATRX knockout lead to increases in accumulated DNA damage, as
DNA repair capacity is lowered in these cells.

A

B

Figure 4.7: U87 ATRX KO cells have increased γH2AX and 53BP1 levels
U87 cells were analyzed at 0, 10 and 24 hours after 1mM HU treatment. Cells
were counted as positive with greater than 20 γH2AX and 10 53BP1 foci. ATRX
KO is shown in gray and IDH1 R132H is shown with a dashed line.
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I then performed a comet assay to determine if an increase in DNA breaks was occurring in
the LN229 cells. I found that there were trending increases in both baseline DNA breaks as well
as breaks after radiation (Figure 4.8). This could also indicate an increase in double strand
breaks, and further work could expand to more time points to better understand this result. It
would be interesting for future work to see if this repeated in the U87 cell line.

Figure 4.8: Increase in double strand breaks in LN229 ATRX KO cells
Comet assay was performed to identify double strand breaks in LN229 cells. Cells were
harvested 1 hour after 10 Gy radiation, or no treatment. Average comet tail moment over
3 independent experiments were graphed. In each experiment at least 50 comet tails were
analyzed using Open Comet (Gyori et al., 2014).
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4.4. Drug Screen
Since ATRX loss leads to a DNA repair defect I then performed a drug screen aimed to
exploit this deficiency. This was done by focusing the screen on DNA damaging agents and
repair inhibitors. In addition to therapeutic relevance, the specific targets of inhibitors that show
differential sensitivity can be further studied to provide mechanistic insights into the DNA repair
defect in ATRX KO cells.
I performed a preliminary drug screen using 24 DNA repair related compounds. Each
compound was used at 7 concentrations in a 96 well plate and fixed 96 hours after treatment
(Figure 4.9). After counting Hoechst dye-stained nuclei, I was able to determine whether ATRX
knockout cells were more sensitive to any of the compounds tested (Figure 4.9A). In this drug
screen, I tested both of the identical clones from my clone screen as a control (Figure 3.2), listed
as ATRX KO and ATRX KO repeat (Figure 4.9B).
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Figure 4.9: Drug Screen in LN229 ATRX KO cells shows sensitivity to Chk1 inhibitors
A) Schematic of drug screen technique. Each column of a 96 well plate has a different
drug to allow for screening of multiple compounds. B) Representative images of
successful hits from the screen, showing that nearly all hits inhibit CHK1. ATRX KO and
ATRX KO repeat are the two identical clones 87 and 180 found in the screening process
(Chapter 3.2)

Most compounds did not show sensitivity differences between WT and ATRX KO cells.
However, few did show approximately two-fold differences in IC50. Interestingly, three of the
five compounds with these differences inhibited CHK1 (Figure 4.9B). This could also imply
increased replication stress such as seen with the foci data, as CHK1 is an important component
of the ATR pathway that signals for replication stress (Saldivar et al., 2017). However, since

54

these differences were small, it appears that adding DNA damaging agents will be needed to
enlarge the differences between the parental and ATRX knockout cells.
Additionally, adding other common mutations in genes such as IDH1 may be necessary to
find larger differences. To investigate this, I overexpressed the R132H mutant in the ATRX KO
cell line (Figure 4.10).
I then screened compounds in the LN229s to identify ones that specifically target these
double mutant cells. I have compared the doxycycline inducible R132H LN229 cells with and
without ATRX KO to determine changes in sensitivity to DNA repair inhibitors and DNA
damaging agents. I tested 20 compounds and found a few possible changes in sensitivity in the
double mutants (Figure 4.11).

Figure 4.10: Expression of IDH1 R132H in LN229 ATRX KO cells
Screen of multiple single cell clones of LN229 ATRX KO with IDH1 R132H overexpression.
Mutant IDH1 expression was induced with 2µg/ml of doxycycline for at least 48 hours before
analysis. Clone 3 and 6 were chosen for further study.
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Figure 4.11: Drug screen comparing WT, ATRX KO, IDH1 R132H and double mutants
Drug screen was performed as seen in Figure 4.9A. IC50 of each drug was compared
between the four cell lines. The IC50 between A) R132H and B) ATRX KO and the double
mutant were divided and the ratio plotted. Ratios greater than 1 indicate greater sensitivity
in the double mutant cells than the individual mutations. A) shows compounds sensitive
specific to ATRX KO and B) shows compounds sensitive to R132H addition. PD407824
is a Wee1/CHK1 inhibitor and TCS2312 is a CHK1 inhibitor

While TMZ appeared to have a difference in sensitivity (Figure 4.11A), this was found to be
an artifact of the screen and unable to be repeated. However, it is interesting that two of the
CHK1 inhibitors (PD407824 and TCS2312) were found to be slightly more sensitive to double
mutant sensitivity than ATRX KO alone. As these hits were found in the previous drug screen
(Figure 4.9B) it is promising that CHK1 is an interesting target in ATRX KO cells as well as the
double mutant cells.
4.5. Discussion
The investigation of DNA repair capacity in the LN229 and U87 ATRX KO cell lines
provides great evidence that ATRX KO can be exploited therapeutically. There is evidence of
both homologous recombination defect as well as increased replication stress in these cells. This
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was found through plasmid reporter assays, increases in γH2AX and 53BP1 foci after
hydroxyurea treatment and sensitivity to CHK1 inhibitors.
While the decrease in homologous recombination is interesting, further work could be done
to explore this mechanism. Difficulties with the toxicity of the assay led to variations in results
and an inability to combine with control siRNAs to central DNA repair proteins such as BRCA1
for HR and Ku80 for NHEJ. A great assay to minimize these toxicities would be the EJ-DR
reporter assay that has both HR and NHEJ assays integrated into the cell line so no transfection
is necessary (Bindra et al., 2013). Unfortunately, this assay is in the U2OS cell line, which
already lacks ATRX expression (Lovejoy et al., 2012). Over expression of ATRX using a
plasmid has so far been unsuccessful, perhaps due to IS10 insertion (Valle-García et al., 2014)
and is currently being optimized. Additional studies that could be done to look at homologous
repair deficiency are foci studies of HR markers (BRCA1, RAD51, BRCA2). However, it was
decided to prioritize the replication stress phenotypes in these cells for future work.
The increase in γH2AX and 53BP1 foci after hydroxyurea treatment indicates an increase in
replication stress. While this was seen at later timepoints than in the literature (Leung et al.,
2013), this could suggest that the ATRX KO cells are stalling in S phase as they have more
difficulties with the stress caused by the lack of nucleotides due to hydroxyurea. This implies
that ATRX KO cells are more sensitive to changes during replication, as they may already have
low levels of replication stress that are heightened with damage. It is interesting that damage at
baseline is seen in the U87 cell lines but not in the LN229. This could indicate that LN299s have
increased capacity to handle replication stress than the U87s but this capacity is not enough to
counteract the stress from hydroxyurea treatment.

57

To further investigate if increases in double strand breaks are occurring in the LN229s, I
performed a comet assay. While not statistically significant, there is a trend for an increase in
double strand breaks not only at baseline but also 1 hour after radiation. This further supports the
idea that as these cells have an inability to repair DNA, especially when damage levels are
increased by DNA damaging agents such as radiation. Further work could be done to identify if
this occurs in the U87 cell line as well as later time points to increase the number of cells going
through replication after radiation. It would also be interesting to see if this would be in
enhanced in the double mutant IDH1 and ATRX KO cells. IDH1 R132H mutant cells have been
shown previously to have increased comet tails and so the addition of ATRX knockout could
lead to further differences (Sulkowski et al., 2017)
While the work in DNA repair capacity showed some differences between WT and mutant,
very little differences were seen in the drug screen. This could be partially due to the increase in
growth rate seen in the ATRX KO masking the differences in survival with these compounds. It
is interesting however that despite the differences only being slight that they consistently showed
sensitivity to CHK1 inhibition. As CHK1 is an important factor in the signaling of replication
stress (Saldivar et al., 2017), this further supports that replication stress could be occurring in
these cells. However, it seems that the differences in growth rate as well as unknown background
mutations in these cell lines are making them resistant to different DNA repair inhibitors, and so
focus was shifted to the immortalized astrocyte cell line for further drug screens.
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5. LN229 ATRX KO CRISPR Screen
5.1. Introduction
CRISPR/Cas9 is a powerful molecular tool that can be used for additional purposes than
creating model cell lines as described in Chapter 3. This technique can also be used to identify
key genes related to a gene of interest. Referred to as a CRISPR screen, this assay has been used
countless times to further identify mechanisms of survival in different cell lines and potential
therapeutic targets for cancer cells.
In this method, numerous CRISPR/Cas9 gRNAs are created to make a library of potential
gene knockouts. These are transduced into cells at a low multiplicity of infection, so that cells
receive at most one CRISPR gRNA from the library. The cells are then put under selection and
studied overtime by harvesting samples of cells periodically for next generation sequencing. This
can be done with untreated cells, or while treating with a compound of interest. Each sample is
then barcoded through PCR amplification and next generation sequencing is performed to
identify each individual gRNA present in each sample. If a gRNA decreases in representation
over time, this implies that cells with this gRNA have a growth disadvantage and so are sensitive
to the loss of that gene. Conversely gRNAs that increase in representation give a growth
advantage compared to controls which can also be studied mechanistically. Comparing how
these population changes occur between drug treatments or cell lines gives targets of interest for
further study.
For my work, I chose to do a targeted CRISPR screen focused on DNA damage response
using a library from the Gupta lab (Feng et al., 2019). This library contains 284 genes that are
known or suspected to be involved in DNA repair. Many of these proteins are involved in
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multiple pathways, creating a very interconnected map of genes in this study (Figure 5.1). Using
a more targeted approach for this CRISPR screen allows for increased coverage for each gene
(10 or more gRNAs per gene). These and over 1000 non targeting control gRNAs give a total of
nearly 4000 gRNAs in the library. The gRNAs for each gene can then be pooled and their
representation in the population can be compared to the non-targeting controls over time.

Figure 5.1: Genes in CRISPR screen library
284 genes in multiple DNA damage response pathways were tested in this screen (left).
Many genes overlap in these pathways, leading to a complex network (right).
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I performed this screen in duplicate, with the second screen being more robust than the first
through increased cell sample size. These screens gave multiple interesting hits to further pursue,
such as XPC, KDM2A, and UHRF1 that are more sensitive to ATRX loss compared to WT.
Further mechanistic insights into ATRX’s role in DNA repair can be elucidated with future work
understanding these CRISPR screen hits.
5.2. Initial CRISPR Screen
I performed a CRISPR screen to identify targets that are synthetically lethal (see Chapter 3.1)
with ATRX knockout. I transduced both cell lines with the CRISPR library pool targeting 284
DNA repair related genes. After puro selection, I harvested the cells over two weeks and purified
the genomic DNA. I then performed a PCR of the CRISPR guide sequence incorporated into the
genome and barcoded each sample through a second PCR (Figure 5.2). While there are large
bands from the primers annealing to each other, it was possible to isolate the top band and send
for next generation sequencing. Round 3 PCR was also performed to validate the success of the
amplifications from the first two rounds.

61

Figure 5.2: Representative CRISPR Screen PCR
CRISPR insertion region is amplified in round 1 and barcoded in round 2. Round 3 is
performed to confirm successful amplification.

The next generation sequencing data was then processed by Dr. Gregory Breuer. I received
the beta scores for each gene tested, which combines the effect of the gene as well as the
confidence in that effect. To increase the power of the experiment, he pooled each of the
different day results into one beta score per gene. By looking at the difference between these
scores I can determine potential synthetic lethal targets with ATRX (Figure 5.3).
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Figure 5.3: First CRISPR Screen beta scores
Beta scores were calculated as -log10(p-value)*(effect size). Plot shows the deviation of
the WT and ATRX mutant score from each other (y=x). An increased differential effect is
highlighted with a darker point. Beta scores were calculated by Greg Breuer and plot was
created by Sam Friedman.

In Figure 5.3, the color of each point indicates how far each gene of interest deviated
from equal sensitivity in WT and ATRX KO cells. Points above the line indicate gRNAs that
were more represented in the WT than the ATRX KO. This suggests that the ATRX KO cells
were more likely to lose this gene through the experiment as these cells were less likely to
survive. These genes such as XPC and UHRF1 could be potential targets for synthetic lethality
with ATRX loss. While less therapeutically relevant, the points below the equal sensitivity line
can also give insight to mechanistically what genes are less relied on when ATRX is lost. These
could be genes that are in the same pathways as ATRX, as their loss is epistatic with ATRX loss.
In this screen CDK4 and MNAT1 are both cell cycle proteins, suggesting that there are already
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irregularities in cell cycle when ATRX is knocked out, making these genes less necessary for
survival.
5.3. Improved CRISPR Screen
After performing the initial screen, I learned many ways to increase the robustness of the
screen. I repeated the screen and greatly scaled up the cells, harvesting 8 million cells for each
cell line instead of the 1-2 million from the initial screen. This larger input size allowed for that
the days harvested to be analyzed independently, and so differences over time were able to be
analyzed. The overall trends can be seen in Table 5.1. The difference calculation is now able to
involve the representation over time due to the increased power.

Gene
sgRNA
WT_D4
XRCC3
10 0.10
POLD2
10 0.15
CCNH
10 0.00
UHRF1
10 -0.12
PARP3
10 0.09
CLK2
10 0.10
UNG
10 0.13
POLD1
10 0.12
GTF2H3
9 -0.04
XAB2
10 -0.16
KDM2A
10 -0.02
FANCC
10 0.03
GTF2H1
10 0.01
DCLRE1B
10 -0.09
LIG1
10 0.44
NUDT1
10 0.28
EXO1
10 -0.06
CUX1
10 0.01

WT_D7 WT_D10 WT_D14 ATRX_D4 ATRX_D7 ATRX_D10 ATRX_D14 diff
-0.04
-0.27
-0.71
-0.25
-0.48
-0.94
-1.47
-1.43
-0.25
-0.33
-0.57
-0.37
-0.63
-0.92
-1.24
-1.27
-0.52
-0.80
-1.00
-0.14
-0.93
-1.28
-1.71
-1.20
-0.28
-0.71
-1.14
-0.23
-0.60
-1.23
-1.70
-1.07
0.14
-0.01
-0.04
-0.15
-0.41
-0.51
-0.61
-1.07
0.08
-0.12
-0.05
-0.25
-0.35
-0.59
-0.65
-1.07
0.09
0.11
0.01
-0.08
-0.32
-0.44
-0.50
-1.06
-0.16
-0.50
-0.88
-0.29
-0.76
-1.05
-1.36
-1.03
-0.11
-0.47
-0.62
-0.10
-0.67
-0.94
-1.15
-1.01
-0.43
-0.64
-0.52
-0.70
-0.91
-1.05
-1.10
-0.99
-0.08
-0.14
-0.39
-0.28
-0.48
-0.67
-0.83
-0.97
0.08
-0.06
-0.05
-0.31
-0.36
-0.40
-0.68
-0.96
-0.38
-0.59
-0.78
-0.07
-0.62
-1.09
-1.22
-0.93
-0.20
-0.29
-0.53
-0.03
-0.44
-0.81
-0.94
-0.93
0.37
0.24
0.14
-0.09
-0.14
-0.21
-0.34
-0.93
0.32
0.22
0.12
-0.20
-0.15
-0.30
-0.28
-0.92
-0.19
0.03
-0.14
0.16
-0.30
-0.53
-0.50
-0.92
0.15
0.14
0.11
-0.29
-0.19
-0.37
-0.29
-0.92

Table 5.1: Top hits from repeat CRISPR screen
Genes with greatest difference between WT and ATRX KO cells. Difference was calculated
as the sum of WT day 10 and 14 subtracted from ATRX KO day 10 and 14. Negative values
indicate loss in representation in the screen.
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In this screen, the top results were genes such as the Rad51 paralog XRCC3, replication and
repair polymerase polδ and the chromatin modifier UHRF1. The top overrepresented gene in the
ATRX KO cells was BRCA1, which can indicate that there is a homologous recombination
defect in the ATRX KO cells that causes them to less reliant on BRCA1. These genes occurred
in many repair pathways, but most were in the nucleotide and base excision repair pathways (
Table 5.2). Since many genes are in multiple pathways, many pathways had multiple hits.

KEGG Pathway

Genes

Nucleotide excision repair

6

Base excision repair

5

Mismatch repair

4

DNA replication

3

Basal transcription factors

3

Chromosome and associated proteins

3

Homologous recombination

3

Cell cycle

1

Fanconi anemia pathway

1

Table 5.2: Top pathways for CRISPR screen hits
CRISPR screen hits were seen in many repair pathways as well as DNA replication and some
chromatin associated factors.
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5.4. Comparison of Screens
When comparing the hits from the two screens, it quickly becomes apparent how the change
in initial cell number helped strengthen the results. As seen in Figure 5.4, the overall range in
difference in beta scores is much higher in the second screen than the first. Due to this, different
thresholds were used to determine the top scoring gRNAs, which can be seen as a red line in
Figure 5.4.
Despite the differences in robustness, 25% of the top 40 hits from both screened overlapped,
showing the validity of even the smaller screen (Figure 5.5). These overlapping top genes tend to
fall into the nucleotide and base excision repair pathways as well as chromosome and associated
proteins. However, those in bold (CLK2, KD2A and UHRF1) were the genes with the greatest
difference in both screens and were chosen for preliminary validation.

Figure 5.4: Comparing differences in beta scores between screens
Differences in beta scores as indicated in Figure 5.3 and Table 3.2 were plotted from lowest to
highest. Red dashed line indicates cut off for hits chosen for further analysis.
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Figure 5.5: Overlap of hits between CRISPR screens
While both CRISPR screens differed in sample size, 25% of the top hits overlapped
between screens. Genes in bold were at the very top of both screens and selected to be
validated first.

5.5. Hit Validation
To begin validating these hits, I began by first testing the top result from the first screen,
XPC. XPC is known for its role in the sensing of large legions for nucleotide excision repair but
has also been found to have a role in chromatin modification and metabolism (Nemzow et al.,
2015). To investigate if XPC is required for ATRX KO cell survival, I compared cell growth in
WT and ATRX KO cells with siXPC. Despite the screen being performed in LN229s, I also
repeated this in the U87 cell lines to control for a cell line specific sensitivity.
XPC siRNA was toxic in both WT and KO cell lines compared to the RISC free control.
However when comparing the normalized growth in each cell line, it can be seen that siXPC is
significantly more toxic in the ATRX KO than the WT (Figure 5.6) This suggests that ATRX
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KO is more sensitivity to loss of XPC, which preliminarily validates the result from the CRISPR
screen.

A

B

C

Figure 5.6: XPC knockdown leads to greater sensitivity in ATRX KO cells than WT
A-B) Normalized cell growth after 72 hours of siXPC or RISC free control. Cells were
transfected in 6 well dish with siRNA 72 hours before cells were split into 96 well plate
and remaining used for western blot analysis. Growth normalized to RISC free for each
cell line. Experiment performed in both A) LN229s and B)U87 cells. C) Western blot
showing XPC levels in the LN229 cells. U87 cells did not have enough cells for XPC
levels to be tested.
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After the second screen the top result, XRCC3, as well as the three top genes that overlapped
in both screens (CLK2, KDM2A and UHRF1) were tested using siRNA in a similar manner to
the siXPC. siXRCC3 was found to be very toxic and so no clear difference was seen between
cell lines (Figure 5.7). siKDM2A had the greatest difference between WT and ATRX KO while
siCLK2 had a minor difference (Figure 5.7). Further study of KDM2A’s role as a histone
demethylase and its role in ATRX KO cells would be interesting for further study.

Figure 5.7: siRNA validation of top CRISPR screen hits
Normalized cell growth after 72 hours of siRNA or RISC free control. Cells were transfected in
6 well dish with siRNA 72 hours before cells were split into 96 well plate for growth rate
analysis.
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To more robustly validate the CRISPR screen, I chose single gRNAs from the pool to create
new cell lines for long term clonogenic survival assays. Using the beta scores of each individual
guide RNA (supplied by Dr. Gregory Breuer), I chose gRNAs that represented the second-best
result to avoid generally toxic or nonfunctional guides without biasing the validation to the best
available gRNA. For example, for CLK2 I chose gRNA 2 (shown in green) as the second-best
gRNA in the pool for further analyze (Figure 5.8 left). This representation can also show the
overall trend in survival. For BRCA1 (Figure 5.8 right) you can see while each gRNA decreased
in representation overtime, this was much more variable in the ATRX KO cells. This is what
caused BRCA1 to be the most overrepresented gRNA in the ATRX KO cells compared to WT.
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Figure 5.8: Representative individual gRNA results used for validation
Each triangle color represents a different gRNAs representation in the screen overtime.
Comparison of trends in both WT and ATRX KO cells were done to choose the ideal gRNA
for repeat validation. For CLK2 the green gRNA was chosen and for BRCA1 the brown
gRNA was chosen for further study.
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Once these gRNAs were chosen, they were cloned into the LCV2 system for transduction
into the LN229s (Sanjana et al., 2014). After much optimization of the cloning process, CUX4,
CCNH and UHRF1 were the first genes with gRNAs successfully cloned into the LCV2 plasmid
and to be tested through a clonogenic survival assay.
As seen in Figure 5.9, while there was no significant difference in survival between CUX4
and CCNH there is a nearly-significant difference with UHRF1. UHRF1, which binds H3K9
methylation to maintain DNA methylation after mitosis (Rothbart et al., 2012), was very toxic to
both cell lines despite not seeing this toxicity in the siRNA experiment (Figure 5.7). Further
validation of this result would be very interesting especially if toxicity can be reduced with an
inhibitor instead of complete knockout.

Figure 5.9: Validation of CRISPR Screen hits through clonogenic survival assay
Survival of each cell line after two weeks. Growth was normalized to the parental
WT or ATRX KO untreated survival.
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5.6. Discussion
CRISPR screens are a great tool for probing for specific genes that interact with or rely on a
gene of interest. Using a specific screen of only genes in certain pathways allows for better
coverage of each gene and allows for a smaller, more robust screen. After performing two
duplicate CRISPR screens, I have several hits that can be further validated. These include the top
hit from the first screen, XPC and two that were seen at the top of both screens KDM2A and
UHRF1. These genes all could be involved with ATRX function, and perhaps could be inhibited
to cause selective sensitivity to ATRX loss.
XPC (xeroderma pigmentosum complementation group C) is a protein involved in
recognizing DNA legions and recruiting additional repair factors for nucleotide excision repair
(Nemzow et al., 2015). While this might seem independent of ATRX function, XPC has been
implicated in other DNA repair process as well. XPC has been found to be required for
ATM/ATR activation after UV legions (Ray et al., 2009, 2013). As there is evidence in my work
of ATRX loss leading to increased ATR activation and γH2AX increases (Chapter 6.4 and 4.3),
further disruption of this signaling pathway could lead to increased sensitivity in ATRX KO
cells. Additionally, there is some evidence that the XPC is required for telomere stability (Stout
and Blasco, 2013). Since ATRX loss is associated with telomere stability as well (Clynes et al.,
2015), losing both XPC and ATRX might lead to heightened telomere instability, which in turn
leads to cell death. Either of these hypotheses of mechanism of selective sensitivity would be
very interesting to further analyze.
Another interesting hit from the siRNA growth validation experiments is KDM2A. KDM2A
is a histone demethylase that targets H3K36 methylation (Vacík et al., 2018). KDM2A is also
associated with similar structured repetitive sections of chromatin as ATRX such as centromeric
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heterochromatin (Frescas et al., 2008) and rRNA (Tanaka et al., 2010). As ATRX is also a
chromatin modifier in these regions (Udugama et al., 2015, 2018; Voon et al., 2015), it would be
interesting to investigate how the histone methylation changes after KDM2A depletion when
ATRX KO has already caused epigenetic changes in these regions. The chromatin at these more
structured regions may no longer be able to be properly maintained leading to greater DNA
damage and increased cell death.
UHRF1 and ATRX also have interesting overlapping functions. Similar to KDM2A, UHRF1
also acts on histone H3. Specifically, UHRF1 binds to H3K9 methylation and recruits DNA
methylation machinery to methylate the daughter strand during replication (Rothbart et al.,
2012). Since ATRX loss is also modulating H3 levels and binds to H3K9 methylation (Iwase et
al., 2011) it would be interesting to identify how these two proteins interact. Perhaps the lack of
both of these proteins binding will lead to increased genomic instability. Additionally, the
frequently cooccurring mutation with ATRX, IDH1 R132H, causes increases in H3K9
methylation levels (Sulkowski et al., 2020). Understanding the chromatin state with each of these
mutations would be very interesting to further elucidate their mechanisms.
Each of these hits leads to very interesting mechanistic questions that could allow for a
better understanding of ATRX’s function. Additionally, inhibitors to any of these proteins would
be potential therapeutic targets in ATRX mutant cancers to future explore. While more validation
needs to be done, these hits are very promising and would be fascinating to pursue further.
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6. ATRX KO immortalized astrocytes have sensitivity to PARP
inhibitors due to increased replication stress
This chapter is adapted from work to be published:
Garbarino, J., Eckorate J., Jensen, R., and Bindra, R.. Loss of ATRX confers DNA repair
defects and PARP inhibitor Sensitivity. Translational Oncology (in revision) 2021.
6.1. Introduction
ATRX (Alpha Thalassemia Retardation syndrome X-linked) has been studied extensively for
its role in the syndrome it is named after, but was only recently found to have importance in
cancers such as pancreatic neuroendocrine tumors (PanNet) (Chan et al., 2018) and gliomas
(Reifenberger et al., 2016). ATRX is a ATP dependent chromatin modifier that helps deposit
histone 3.3 (H3.3) into the genome at heterochromatin (Voon et al., 2015), pericentromic regions
(Iwase et al., 2011), rDNA (Udugama et al., 2018) and other structured regions. ATRX is now a
diagnostic marker for gliomas due to its frequency and distinguishing characteristics, as nearly
30% of younger glioma patients have an ATRX mutation (Haase et al., 2018). ATRX loss is also
necessary but not sufficient for the Alternative-Lengthening of Telomeres pathway, which occurs
in 10-15% of tumors (Voon et al., 2016). Since its discovery in cancer, ATRX has been
implicated in a number of DNA damage response (DDR) pathways, including replication stress
response (Clynes et al., 2015; Huh et al., 2016; Leung et al., 2013; Wang et al., 2019),
homologous recombination (HR) (Juhász et al., 2018; Raghunandan et al., 2019) and nonhomologous end joining (NHEJ) (Koschmann et al., 2016). However, it has yet to be determined
whether loss of ATRX confers sensitivity to DDR inhibitors in glioma models.
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An important pathway studied in these processes is the signaling of replication stress. This is
done through ATR activation. Ataxia telangiectasia and Rad3‑related (ATR) is a kinase that is
recruited to single strand breaks by Replication Protein A (RPA). ATR phosphorylates RPA (at
S33) as well as other proteins to activate DNA repair pathways (Murphy et al., 2014; Saldivar et
al., 2017; Vassin et al., 2009). CHK1 is another of these proteins activated by ATR
phosphorylation (at S317 and S345) which halts the cell cycle for replication stress to be
resolved as well as activating downstream, DNA repair factors (Smith et al., 2010). Investigating
the signaling in this pathway allows for better understanding for the levels of replication stress in
a cell.
Additionally, ATRX loss often co-occurs with glioma-associated mutations in other
genes, such as isocitrate dehydrogenase-1 and -2 (IDH1/2). IDH1/2 encode citric acid cycle
enzymes which convert isocitrate into alpha-ketoglutarate (αKG), and neomorphic mutations in
these genes converts alpha-ketoglutarate into the oncometabolite, 2-hydroxyglutarate (2-HG).
2HG competitively inhibits αKG-dependent dioxygenase proteins, which induces profound
epigenetic alterations and impaired differentiation (Lu et al., 2012; Xu et al., 2011). Previous
work recently demonstrated that 2HG induces HR defects and sensitivity to poly(ADP)-ribose
polymerase (PARP) inhibitors (Lu et al., 2017; Molenaar et al., 2018; Sulkowski et al., 2017,
2020; Wang et al., 2020). However, it has yet to be fully elucidate how ATRX and IDH1/2
mutations interact with regard to modulation of the DDR. One study reported that loss of ATRX
induces impaired NHEJ (Koschmann et al., 2016), but a subsequent study from the same group
suggested that ATRX loss actually increases DDR activity specifically in the context of IDH1/2
mutations (Núñez et al., 2019). These studies were largely performed in rodent models, and thus
additional data are required in human glioma models.
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To further investigate the function of ATRX function in the DDR, I created isogenic wildtype (WT) and knockout (KO) ATRX model cell lines using CRISPR-based gene targeting and
performed a focused drug screen for novel synthetic lethal interactions with DDR inhibitors and
DNA damaging agents. These studies revealed that loss of ATRX confers sensitivity to
poly(ADP)-ribose polymerase (PARP) inhibitors, which was linked to an increase in replication
stress, as detected by increased activation of the ATR signaling axis. I found that the magnitude
of PARP inhibitor sensitivity was equal in cell line models with ATR loss and IDH1 mutations
alone, although no further sensitization was observed in combination, suggesting an epistatic
interaction. Finally, I observed enhanced synergistic tumor cell killing in ATRX KO cells with
combined ATR and PARP inhibition, which is commonly seen in HR-defective cells (Kim et al.,
2017; Lloyd et al., 2020; Schoonen et al., 2019). Taken together, these data reveal that ATRX
may be used as a molecular marker for DDR defects and PARP inhibitor sensitivity, which is
independent of IDH1/2 mutations.
6.2. Validation of ATRX knockout
Using the platform discussed in Chapter 3.3, I found human astrocyte clones with successful
ATRX knockout (Figure 3.10). To further validate knockout in this clone, I performed western
blots to confirm loss of the ATRX protein (Figure 6.1A). I then used sequencing analysis
combined with TOPO cloning to confirm biallelic loss of ATRX through a 26 and 11 base pair
deletion (Figure 6.1B).
ATRX loss has been associated with cell cycle changes (Leung et al., 2013), so I further
characterized the growth patterns and patterns of cell cycle phase distribution in the WT and
ATRX KO models. I determined that the ATRX KO cell line grew at the same rate as the
parental astrocytes, as seen previously with ATRX KO in HeLa cells, and did not detect any
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differences in plating efficiencies (Juhász et al., 2018; Leung et al., 2013) (Figure 6.1C). This
differs from the LN229 and U87 clones that have growth rate and morphology differences
between WT and ATRX KO which made the astrocytes a more robust isogenic pair for
comparison (Figure 4.2 and Figure 4.4). I also found that a significantly larger percentage of
ATRX knockout cells were cyclin A-positive in comparison to their wild-type counterparts
(Figure 6.1D), which suggests an increased S/G2 population in ATRX KO cells.
I also found that these cells have similar functional defects similar to those previously
reported in ATRX-deficient cells, such as pyridostatin (PDS) sensitivity (Figure 6.1E). As a Gquadruplex stabilizer, PDS has been found to specifically target ATRX deficient cells as H3.3
deposition is important for resolution of this DNA structure (see Chapter 1.7) (Wang et al.,
2019). Taken together, these data confirm the ability to characterize, and functionally validate
ATRX WT and KO isogenic GBM model cell line pairs.
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Figure 6.1 Validation of immortalized astrocyte ATRX KO cell line
A) ATRX KO clone in immortalized astrocytes further validated through western blot and
immunofluorescence. B) Sequencing data showing biallelic knockout of ATRX. C)
Representative plating efficiency in parental and wildtype cell lines. D) Sensitivity to
pyridostatin after 14 day Clonogenic survival assay. Cells were treated with 0.1, 0.5 and 1µM
pyridostatin. E) Cyclin A staining was performed, and positive cells were scored through
immunofluorescence intensity greater than 20,000 in 16-bit images.
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6.3. Drug screen with ATRX KO cells shows PARP inhibitor sensitivity
Given previous evidence of a possible role for ATRX in the DDR, I performed a focused
screen with unique DNA damaging agents and repair inhibitors to identify potential synthetic
lethal interactions that are associated with ATRX loss. Screening was performed in the active
dose ranges for the molecules, and ATRX WT and KO cell lines were analyzed in parallel.
Screening data is shown in Figure 6.2, along with a summary table of the calculated IC50s for
each drug in the ATRX WT and KO cell lines. I included pyridostatin as a positive control
because of the known selectivity for ATRX KO cells. I observed a detectable selectivity (albeit
modest) against ATRX KO versus WT cells, which had also been seen in the clonogenic survival
assays during the initial validation studies with these model lines (shown in Figure 6.1). I also
found that treatment with the Wee1 inhibitor, MK1775, also selectively targeted ATRX KO
cells, which is consistent with previously published studies (Liang et al., 2019). I detected a
robust synthetic lethal interaction between two PARPi’s, olaparib and BMN673 (talazoparib) and
loss of ATRX, with olaparib having an almost 5-fold reduction in IC50 in ATRX KO cells
compared to WT (Figure 6.2).
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Figure 6.2: ATRX KO astrocytes shows PARP inhibitor sensitivity in DNA repair focused drug
screen.
Representative IC50 plots of short-term viability assays 96 hours after drug treatment. Table
shows ratio of WT/KO IC50 to identify greatest differences in sensitivities.
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I further validated this synthetic lethal interaction in clonogenic survival assays with
olaparib (Figure 6.3A). As shown in the representative crystal violate-stained plates, there are
nearly no surviving ATRX KO colonies at 5µM of treatment with olaparib, despite many
colonies still present with the WT cells.
I then validated this differential PARP inhibitor sensitivity in a glioma cell line, U251,
which I engineered for doxycline (dox)-inducible ATRX knockdown using shRNAs (Figure
6.3B). These ATRX knockdown cells also show sensitivity to olaparib (Figure 6.3C) and BMN673 (Figure 6.3D). PARP inhibitor sensitivity was also further confirmed in a clonogenic
survival assay with olaparib in this dox-inducible shATRX knockdown model (Figure 6.3E).
Collectively, these data suggest that loss of ATRX confers significant sensitivity to PARP
inhibitors.
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Figure 6.3: PARPi sensitivity from drug screen validated in astrocytes and U251s
A) Sensitivity to olaparib in ATRX KO cells after 14 day clonogenic survival assay.
B) Western blot show knockdown of ATRX also leads to PARPi sensitivity in U251s.
sATRX induced with 1 µg/ml of doxycycline for greater than 96 hours prior to
experiment. C) Short term viability assay with olaparib 96 hours after treatment. D)
Short term viability assay with BMN673 96 hours after treatment. E) Clonogenic
survival assay with 1.5µM olaparib 14 days after treatment.

83

6.4. Olaparib leads to increased replication stress in ATRX KO cells
Given the findings that loss of ATRX is associated with a higher fraction of S-phase cells
(Figure 6.1E), and increased sensitivity to PARP inhibitors (Figure 6.3), I considered the
possibility that ATRX KO cells have baseline elevated levels of replication stress.
Phosphorylated RPA (pRPA) foci is a well-established marker for elevated replication stress, as
pRPA coats single-stranded DNA at stalled/collapsed replication forks in direct response to ATR
activation (Murphy et al., 2014; Vassin et al., 2009). I observed elevated levels of pRPA foci at
in untreated cells (Figure 6.4A). These levels were increased after olaparib exposure, and the
induction was significantly greater in ATRX KO versus WT cells (Figure 6.4B). I validated this
phenotype in the dox-inducible U251 shATRX cell line as well (Figure 6.4C). Enhanced pRPA
foci after olaparib exposure also correlated with phosphorylation of another ATR target, Chk1
(Smith et al., 2010), as detected by western blot analysis in ATRX KO cells (Figure 6.4D).
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Figure 6.4: Olaparib leads to increased replication stress in ATRX KO cells.
A) pRPA32 S33 foci in ATRX KO cells compared to WT. Cells with greater than 5 foci were
marked positive. B) pRPA32 S33 foci in immortalized astrocytes. Studies were performed at 24
hours after 5 µM olaparib treatment. Cells with greater than 10 foci were marked positive. C)
pRPA32 S33 foci in U251 cells. Studies were performed at 24 hours after 2 µM olaparib
treatment and in the presence of 1µg/ml doxycycline. Cells with greater than 10 foci were
marked positive. D) pCHK1 S345 western blot was performed 24 hours after 5 µM olaparib
treatment
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As described earlier, ATRX and IDH1/2 mutations co-occur frequently in glioma, and
many have reported that the latter induce HR defects and PARP inhibitor sensitivity (Lu et al.,
2017; Molenaar et al., 2018; Sulkowski et al., 2017, 2020; Wang et al., 2020). After identifying
ATRX KO PARPi sensitivity (Figure 6.3), I wanted to understand how PARPi sensitivity would
change in the context of IDH1/2 mutations. I engineered the immortalized astrocyte ATRX WT
and KO cell line models to contain a dox-inducible IDH1-mutant (R132H) expression vector,
and single cell clones were selected and validated by western blot analysis (Figure 6.5A). In
these cells, the double mutant cells behaved similarly to ATRX deficiency alone with olaparib
treatment (Figure 6.5B) as well as BMN-673 (Figure 6.5C).

A

B

C

Figure 6.5: ATRX KO and IDH1 R132H double mutation leads to equivalent PARPi sensitivity
as either mutation alone.
A) Western blot showing ATRX KO and IDH1 R132H over expression individually and in
combination in astrocytes. R132H induced with 1µg/ml for at least 96 hours. B) Short term
viability assay with olaparib comparing the combination of ATRX KO and IDH1 R132H
mutation to each mutation alone and wild type 96 hours after treatment. C) Short term viability
assay with additional PARPi, BMN673
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Additionally, I also created the combination mutants in the U251 shATRX cell line
(Figure 6.6A), and validated that olaparib sensitivity is equivalent in the shATRX, IDH1-mutant
and double mutant models (Figure 6.6B). The findings in immortalized astrocyte model with
olaparib were also validated in clonogenic survival assays in the U251 model (Figure 6.6C).

A

B
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Figure 6.6 ATRX shATRX and IDH1 R132H double mutation leads to equivalent PARPi
sensitivity pattern as immortalized astrocytes.
A) Western blot showing induction of ATRX knockdown and IDH1 R132H over expression
individually and in combination. 1 µg/ml of doxycycline was used for induction. B) Short
term viability assay with olaparib comparing the combination of shATRX and IDH1 R132H
overexpression to each mutation alone and wild type. C) Clonogenic survival assay with
1.5µM olaparib comparing all four U251 cells lines. Significance was calculated compared
to WT. For B) and C) All four cells lines were treated with 1 µg/ml of doxycycline for at
least 96 hours prior to experiment.
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Finally, ATR and PARP inhibitor combinations have enhanced synergy in tumors with
replication stress and/or HR defects (Kim et al., 2017; Lloyd et al., 2020; Schoonen et al., 2019),
and unpublished work from our laboratory suggests that this combination is particularly effective
against IDH1/2-mutant tumors (Sule et. al., manuscript in revision). In parallel, the data
presented here suggest that loss of ATRX activates the ATR signaling axis and induces
replication stress. These findings lead me to test for synergy with ATR and PARP inhibition. I
observed robust synergy with this combination in the immortalized astrocyte models, with
maximal synergy seen in the ATRX KO cells as compared to WT (Figure 6.7). These data
further highlight the dependence of ATRX KO cells on ATR signaling, and support the use of a
PARP and ATR inhibitor combination against tumors with these mutations.

Figure 6.7: Synergy experiments were performed with olaparib and AZD 6738 (ATR
inhibitor) in both WT and ATRX KO cells. Cells were treated for 96 hours and the Loewe
method was used to calculate synergy.
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6.5. Discussion
I created an isogeneic pair of cell lines in immortalized astrocytes using CRISPR/Cas9-based
gene editing to knockout ATRX. I investigated their DNA repair efficiency through a focused
drug screen of DNA damaging agents and repair inhibitors and discovered that ATRX KO cells
have increased sensitivity to poly(ADP)-ribose polymerase (PARP) inhibitors than WT. I
showed that this was due to increased replication stress as identified through increased activation
of the ATR signaling pathway. In both immortalized astrocytes and U251 cells, I found that
IDH1 mutation and ATRX deficiency combined lead to similar levels of PARPi sensitivity
compared to the individual mutations, suggesting an overlap in function leading to an epistatic
interaction. Additionally, I determined that ATRX KO leads to even greater PARP and ATR
inhibitor synergy than wild-type cells. Overall, this suggests that ATRX is a potential biomarker
for PARP inhibitor sensitivity and DDR deficiencies, independent of IDH1/2 mutation.
This work shows that in different model systems, combined ATRX and IDH1 mutation still
leads to DNA repair defect, despite previous literature suggesting otherwise (see Chapter 1.8)
(Núñez et al., 2019). Interestingly, both the IDH1 and ATRX mutations are known lead to
chromatin aberrations as well as DNA repair defects. IDH1 mutation leads to an increase in
H3K9 trimethylation, an important signal for recruitment of DNA repair proteins (Sulkowski et
al., 2020). ATRX is required for the deposition of H3.3, which can carry this epigenetic mark
and require it for its localization (Iwase et al., 2011; Udugama et al., 2015). Further work is
needed to understand the mechanism of the interplay of these two mutations, but the
combination’s equal sensitivity to olaparib suggests that they affect similar repair pathways.
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7. Discussion
7.1. Conclusions
ATRX is a vital protein for genomic integrity. There is growing evidence of its role in DNA
replication and repair but more work is needed to further characterize this protein. As ATRX is
mutated frequently in cancers such as gliomas, it is also important to identify potential
therapeutic options for patients with this mutation. I created a platform for screening numerous
CRISPR knockout clones and created ATRX knockout in three different cell lines. I then
characterized the DNA repair capacity of each of these cell lines and found DNA repair defects
in each of them linked to homologous recombination and replication stress. I also performed a
CRISPR screen which highlighted the importance of the chromatin modifications made by
ATRX and that ATRX KO cells are more susceptible to increased deregulation of the chromatin.
I also determined that the astrocyte cell line ATRX KO is sensitive to PARP inhibition, which is
caused by increased replication stress in these cells. This sensitivity was epistatic with the
commonly co-occurring IDH1 R132H mutation, which would suggest they act in similar
pathways. There are many possible avenues of future work with these model cell lines, such as
further mechanistic exploration of PARP sensitivity, continued characterization of the CRISPR
screen, analysis of G-quadruplex sensitivity, and understanding the role of ALT in these cell
lines.
7.2. Exploration of possible mechanism for PARP sensitivity
I determined that immortalized astrocytes cell line ATRX KO has sensitivity to PARP
inhibitors in both short- and long-term assays (Figure 6.3). I then investigated the cause of this
sensitivity to be due to increased replication stress. This was supported by increase in pRPA and
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CHK1 levels indicating increase in ATR activation in the ATRX KO cells. Further work can be
done to investigate the mechanism of increased replication stress in these cells.
Multiple groups have shown that ATRX can bind the MRN complex (see Chapter 1.6)
(Clynes et al., 2015; Huh et al., 2016; Leung et al., 2013). Clynes and Huh both hypothesize that
ATRX sequesters the MRN complex to prevent fork degradation and decrease fork stalling.
Without ATRX, this increase in fork degradation leads to increased overall replication stress.
To determine if this is also occurring in my ATRX KO cells, I will perform DNA fiber
combing experiments to investigate fork stalling in these cells in the presence of PARPi. In DNA
fiber combing, nucleotide analogs are incorporated into the genome and the amount of each
analog can be analyze to understand changes in replication. By comparing the lengths of each
analog in the DNA, the amount of stalled or degraded forks can be compared. Then, these
experiments can be repeated in the presence of mirin, an MRE11 inhibitor to determine if
changes in ATRX KO fork stalling no longer occur. This would support that the inhibition of
MRN by ATRX is important for fork protection when PARP is inhibited. I have also begun
optimizing other foci markers to identify stalled forks, such as SMARCAL1, which I hope to
also use to support the hypothesis of increased fork stalling in ATRX mutant cells (Cicconi et al.,
2020). Additionally, I will perform a synergy short term viability assay similar to the one
performed with olaparib and ATR inhibitor (Figure 6.7) but instead with mirin and olaparib. I
hypothesize that mirin will antagonize the increased sensitivity seen with olaparib in the ATRX
KO cells, as it would mimic the inhibition of the MRN complex through ATRX binding. This
would further support that fork protection from MRE11 is necessary for survival from PARP
inhibitor in these cells.
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Another interesting avenue for further investigation is the differences in PARPi sensitivity
between cell lines. While the immortalized astrocytes and U251 cell lines show PARPi
sensitivity, this is not seen in the LN229 and U87 cell lines (data not shown). This could be due
to the changes in morphology and growth rate in these cells masking any differences in cell
growth in the presence of olaparib. However, these cells did show sensitivity to CHK1
inhibition, suggesting they do also rely on CHK1 activation. This indicate that a CHK1 or ATR
inhibitor could potentially sensitize these cell lines to PARPi.
These more PARP resistant glioma lines could have other currently unknown mutations that
lead to PARP inhibitor resistance. For example, even though IDH1 R132H mutation leads to
marked sensitivity to PARPi in other cell lines (Sulkowski et al., 2017; Wang et al., 2020),
LN229s with IDH1 R132H overexpression only have a mild sensitivity to olaparib. Other
mutations in the cells could be compensating for the DNA repair defect. Further understanding
of the overall genetic landscape of each of these cell lines would be needed to better understand
the differences in these cell lines.
7.3. Further validation for CRISPR screen
An additional direction for future study is continued validation of the CRISPR screen results.
While my hypotheses for certain hits are outlined in Chapter 5.6, I also would like to validate
these hits in the more sensitive immortalized astrocyte cell line. As they have a more prominent
sensitivity to PARPi, they might also show greater effects from loss of the different CRISPR hits
than the LN229 cell line shows. It may in fact be beneficial to repeat the screen entirely in the
astrocytes, using the knowledge gained in the original screens to ensure robustness. I can also
further validate these hits in the U87 cell line. I had made attempts to repeat this screen in U87
ATRX KO cell line, however it became very difficult to have enough cells for the assay due to
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their changes in morphologies leading to high confluency at lower cell numbers. Priority for
future study could be given to hits that are validated by all three cell lines, whether or not a
CRISPR screen is completed in all three lines.
Additionally, to focus specifically on PARP inhibition, this screen could instead be done in
the presence of olaparib. In the astrocytes and the U251s, this would allow for more specific
targeting of the factors involved in PARP sensitivity in these lines and could further support the
hypothesis of replication stress in these cells. The LN229s and U87s could also be screened in
the presence of PARP inhibitor and the results compared to those from the astrocytes and U251s.
This could help determine differences in these cell lines to further characterize the components
besides ATRX KO necessary for PARP inhibitor sensitivity in these cells.
7.4. Analysis of G-quadruplex sensitivity in ATRX KO cells
An additional way to characterize these cell lines is further investigation into G-quadruplex
sensitivity. G-quadruplex stabilization was shown to lead to sensitivity in the astrocyte cell line
(Figure 6.1) as well as the U251 cell line (data not shown). I would be very interested to see if
increases in G-quadruplex levels are seen in my ATRX deficient models, as shown by others
(Clynes et al., 2015; Wang et al., 2019). I additionally want to investigate to see if DNA repair
markers after olaparib treatment co-localize with these G-quadruplexes, such as pRPA foci, to
indicate if that these are the sites of replication stress. I also plan to investigate these same
replication stress markers in the presence of G-quadruplex stabilization with and without PARP
inhibitor to identify the importance of G-quadruplex formation in PARPi sensitivity for ATRX
mutant cells.
7.5. Understanding the role of ALT in ATRX KO model cell lines
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Another way to further characterize these cell lines would be to investigate their ability to
perform ALT to extend their telomeres. For example, the immortalized astrocyte line was created
by overexpression telomerase and so would not need ALT for telomere maintenance (Sonoda et
al., 2001). The other glioma cell lines tested, LN229, U87 and U251 have also been shown to
express telomerase, with LN229 having low telomerase expression compared to the others
(Vietor et al., 2000). This makes sense, as all of these cell lines initially expressed ATRX, and so
would be less likely to be using the ALT pathway. However, telomerase expression could be
preventing ALT to occur in these cells, as they do not need to utilize the pathway to maintain
telomere length.
Despite this, initial levels of ALT in these cells will be tested in collaboration with the Chang
Lab, who study telomeres extensively (Chen et al., 2011; Cicconi et al., 2020; He et al., 2009;
Rai et al., 2011). It would be interesting to identify if some ALT phenotypes are present, even in
the presence of telomerase. It will be especially fascinating to see if the double mutant IDH1
R132H and ATRX deficient cell lines have increased ALT phenotype compared to either
mutation alone, as this has been as seen in a previous study (Mukherjee et al., 2018). Telomerase
could also be silenced in these cells and then ALT capacity could be studied further. ALT is an
important pathway in cancer characterized by ATRX loss, and so the ability to test these models
for ALT activity would be a valuable tool for further understanding this process.
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